var title_f27_8_27776="Cystic lesion calcification";
var content_f27_8_27776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solid pseudopapillary neoplasm of the pancreas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidental finding of a 4 cm solid pseudopapillary neoplasm with peripheral calcification in the pancreatic tail of a young woman.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27776=[""].join("\n");
var outline_f27_8_27776=null;
var title_f27_8_27777="CT subdural hemorrhage and cerebral edema";
var content_f27_8_27777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head CT of subdural hemorrhage and cerebral edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT image (axial view) of acute-hyperacute right subdural hemorrhage (arrows) and asymmetric cerebral edema in an eight-month-old male infant who sustained nonaccidental injury (child abuse).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27777=[""].join("\n");
var outline_f27_8_27777=null;
var title_f27_8_27778="Monoclonal antibody generation";
var content_f27_8_27778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71530&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monoclonal antibody generation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An animal is first immunized with a protein of interest. Spleen or lymph node cells are then fused with a myeloma partner. Subsequently, culture supernatants are screened for the presence of antibodies that bind to the immunizing protein. Cells are cloned by limiting dilution to yield a homogenous population.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27778=[""].join("\n");
var outline_f27_8_27778=null;
var title_f27_8_27779="CRS S NP pre post tx";
var content_f27_8_27779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Radiographic features of CRS without NP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus CT scan of a 35-year-old female with CRS without NP before and immediately following intensive medical treatment. The pretreatment sinus CT scan shows near total opacification of both maxillary and anterior ethmoid sinuses. The post treatment sinus CT scan shows complete resolution of these findings. The patient's CRS symptoms completely resolved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Subramanian, HN, Schechtman, KB, Hamilos, DL. A retrospective analysis of treatment outcomes and time to relapse after intensive medical treatment for chronic sinusitis. Am J Rhinol 2002; 16:303. Copyright &copy;2002 Oceanside Publications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27779=[""].join("\n");
var outline_f27_8_27779=null;
var title_f27_8_27780="Imiglucerase (glucocerebrosidase): Drug information";
var content_f27_8_27780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imiglucerase (glucocerebrosidase): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/2/28707?source=see_link\">",
"    see \"Imiglucerase (glucocerebrosidase): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"    see \"Imiglucerase (glucocerebrosidase): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cerezyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerezyme&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Gaucher disease:",
"     </b>",
"     I.V.: Dose is individualized. Initial: 2.5 units/kg 3 times weekly, up to 60 units/kg every 2 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustments are made  based on assessment and therapeutic goals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Most benefits observed with doses of 30-60 units/kg every 2 weeks (Charrow, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=see_link\">",
"      see \"Imiglucerase (glucocerebrosidase): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cerezyme&reg;: 200 units, 400 units [contains mannitol, polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 1-2 hours; may use an in-line, low protein-binding 0.2 micron filter during infusion",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term enzyme replacement therapy for patients with type 1 Gaucher disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cerezyme&reg; may be confused with Cerebyx&reg;, Ceredase&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (&lt;2%), dizziness (&lt;2%), fatigue (&lt;2%), fever (&lt;2%), headache (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&lt;2%), rash (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort (&lt;2%), diarrhea (&lt;2%), nausea (&lt;2%), vomiting (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Backache (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reaction (7%; symptoms may include pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis, hypotension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reactions; injection site burning, swelling, or sterile abscess; peripheral edema, pneumonia, pulmonary hypertension",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known contraindications in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Have been reported (&lt;1%). Most patients have continued treatment with pretreatment (antihistamines and/or corticosteroids) and a slower rate of infusion. Use caution in patients with previous hypersensitivity to, previously treated with, or have developed antibodies to alglucerase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Development of IgG antibodies has been reported in ~15% of patients and has been observed within 6 months from the onset of therapy; antibody formation is rare after 12 months of therapy; may increase risk of hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary hypertension/pneumonia: Has been observed during treatment; causal relationship has not been established as this is a complication of Gaucher disease. Afebrile patients with respiratory symptoms should be assessed for pulmonary hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Registry: A registry has been established and all patients with Gaucher disease, and physicians who treat Gaucher disease are encouraged to participate. Information on the International Collaborative Gaucher Group (ICGG) Gaucher Registry may be obtained at https://www.registrynxt.com, or by calling 1-800-745-4447 (ext.15500).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; however, imiglucerase has been used safely during pregnancy based on available data (Sherer, 2003; Zimran, 2009). Doses of imiglucerase should be based on prepregnancy weight and adjusted as clinically indicated (Granovsky,  2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14722459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A case report described a small amount of imiglucerase excreted into breast milk. The maximum amount of enzyme activity was obtained in the first milk at the end of the imiglucerase infusion; enzyme activity rapidly declined to preinfusion levels (Sekijima, 2010).  Enzyme ingested by a nursing infant would likely degrade in their digestive system (Zimran, 2009). The benefits of nursing to the infant should be weighed against the potential for additional bone loss in the mother (Granovsky, 2011; Zimran, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Cerezyme Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 unit (1): $951.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 unit (1): $1903.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, platelets, liver function tests, IgG antibody formation, acid phosphatase (AP); MRI or CT of liver and spleen, skeletal x-rays, physical exam every 6-12 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cerezyme (AT, AU, BE, BG, CH, CL, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IT, KP, MT, MY, NL, NO, NZ, PL, PT, RU, SE, SG, SK, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Imiglucerase is an analogue of glucocerebrosidase; it is produced by recombinant DNA technology using mammalian cell culture. Glucocerebrosidase is an enzyme deficient in Gaucher's disease. It is needed to catalyze the hydrolysis of glucocerebroside to glucose and ceramide.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.09-0.15 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.6-10.4 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baldellou A, Andria G, Campbell PE, et al, \"Paediatric Non-Neuronopathic Gaucher Disease: Recommendations for Treatment and Monitoring,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2004, 163(2):67-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/14677062/pubmed\" id=\"14677062\" target=\"_blank\">",
"        14677062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charrow J, Andersson HC, Kaplan P, et al, \"Enzyme Replacement Therapy and Monitoring for Children With Type 1 Gaucher Disease: Consensus Recommendations,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2004, 144(1):112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/14722528/pubmed\" id=\"14722528\" target=\"_blank\">",
"        14722528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al, &ldquo;The Management of Pregnancy in Gaucher Disease,&rdquo;",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2011, 156(1): 3-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/21269752/pubmed\" id=\"21269752\" target=\"_blank\">",
"        21269752",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jmoudiak M and Futerman AH, \"Gaucher Disease: Pathological Mechanisms and Modern Management,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2005, 129(2):178-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/15813845/pubmed\" id=\"15813845\" target=\"_blank\">",
"        15813845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pastores GM, Weinreb NJ, Aerts H, et al, \"Therapeutic Goals in the Treatment of Gaucher Disease,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):4-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/15468045/pubmed\" id=\"15468045\" target=\"_blank\">",
"        15468045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sekijima Y, Ohashi T, Ohira S, et al, &ldquo;Successful Pregnancy and Lactation Outcome in a Patient With Gaucher Disease Receiving Enzyme Replacement Therapy, and the Subsequent Distribution and Excretion of Imiglucerasein Human Breast Milk,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2010, 32(12):2048-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/21118740/pubmed\" id=\"21118740\" target=\"_blank\">",
"        21118740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sherer Y, Dulitzki M, Levy Y, et al, &ldquo;Successful Pregnancy Outcome in a Patient With Gaucher&rsquo;s Disease and Antiphospholipid Syndrome,&rdquo;",
"      <i>",
"       Ann Hematol",
"      </i>",
"      , 2002, 81(3):161-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/11904743/pubmed\" id=\"11904743\" target=\"_blank\">",
"        11904743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinreb NJ, Aggio MC, Andersson HC, et al, \"Gaucher Disease Type 1: Revised Recommendations on Evaluations and Monitoring for Adult Patients,\"",
"      <i>",
"       Semin Hematol",
"      </i>",
"      , 2004, 41(4 Suppl 5):15-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/15468046/pubmed\" id=\"15468046\" target=\"_blank\">",
"        15468046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zimran A, Morris E, Mengel E, et al, &ldquo;The Female Gaucher Patient: The Impact of Enzyme Replacement Therapy Around Key Reproductive Events (Menstruation, Pregnancy and Menopause),&rdquo;",
"      <i>",
"       Blood Cells Mol Dis",
"      </i>",
"      , 2009, 43(3):264-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27780/abstract-text/19502088/pubmed\" id=\"19502088\" target=\"_blank\">",
"        19502088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8981 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27780=[""].join("\n");
var outline_f27_8_27780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181998\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182016\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181999\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182008\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182000\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181982\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181970\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181984\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181983\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182021\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182014\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181987\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181974\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299510\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220960\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181979\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181989\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182002\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14722459\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323194\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181980\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038657\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181973\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181986\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/2/28707?source=related_link\">",
"      Imiglucerase (glucocerebrosidase): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/45/39635?source=related_link\">",
"      Imiglucerase (glucocerebrosidase): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27781="Sildenafil: Patient drug information";
var content_f27_8_27781=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sildenafil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     see \"Sildenafil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     see \"Sildenafil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sildenafil&reg;;",
"     </li>",
"     <li>",
"      CO Sildenafil;",
"     </li>",
"     <li>",
"      GD-Sildenafil;",
"     </li>",
"     <li>",
"      PMS-Sildenafil;",
"     </li>",
"     <li>",
"      ratio-Sildenafil R;",
"     </li>",
"     <li>",
"      Revatio&reg;;",
"     </li>",
"     <li>",
"      Teva-Sildenafil;",
"     </li>",
"     <li>",
"      Viagra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat impotence.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high pressure in the lungs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702921",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sildenafil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you use drugs called \"poppers\" like amyl nitrite and butyl nitrite.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been told not to have sex by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke within the last 6 months, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have ulcer disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other drugs used to treat a change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eyesight changes may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change or loss of eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Viagra&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes to 4 hours before sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Revatio&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Viagra&reg;",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11046 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27781=[""].join("\n");
var outline_f27_8_27781=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220995\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220996\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026271\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026273\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026272\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026277\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026278\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026280\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026275\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026276\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026281\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026282\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=related_link\">",
"      Sildenafil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=related_link\">",
"      Sildenafil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27782="Ligation infundibulopelvic ligm";
var content_f27_8_27782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77097&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Suture ligation and placement of a suture tie on the infundibulopelvic ligament during gynecologic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 456px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27782=[""].join("\n");
var outline_f27_8_27782=null;
var title_f27_8_27783="Vigabatrin: Drug information";
var content_f27_8_27783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vigabatrin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/614?source=see_link\">",
"    see \"Vigabatrin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"    see \"Vigabatrin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11238848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8107369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Refractory complex partial seizures:",
"     </b>",
"     Oral: Initial: 500 mg twice daily; increase daily dose by 500 mg at weekly intervals based on response and tolerability. Recommended dose: 3 g/day. (",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling suggests that initial doses up to 2 g/day may be considered in patients with severe seizures.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     To taper, decrease dose by 1 g/day on a weekly basis",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"      see \"Vigabatrin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunctive treatment of seizures (Canadian labeling; not in U.S. labeling):",
"     </b>",
"     Children: Oral: Initial: 40 mg/kg/day divided twice daily; maintenance dosages based on patient weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-15 kg: 0.5-1 g/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16-30 kg: 1-1.5 g/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     31-50 kg: 1.5-3 g/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;50 kg: 2-3 g/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infantile spasms:",
"     </b>",
"     Children 1 month to 2 years: Oral: Initial dosing: 50 mg/kg/day divided twice daily; may titrate upwards by 25-50 mg/kg/day every 3 days to a maximum of 150 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     To taper, decrease dose by 25-50 mg/kg/day every 3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory complex partial seizures:",
"     </b>",
"     Adolescents &ge;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refractory complex partial seizures: Refer to adult dosing. Initiate at low end of dosage range; monitor closely for sedation and confusion.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F234021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50-80 mL/minute: Decrease dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-50 mL/minute: Decrease dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10-30 mL/minute: Decrease dose by 75%",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14932727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied. However, does not undergo appreciable hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sabril&reg;: 500 mg/packet (50s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sabril&reg;: 500 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for suspension, oral [sachets]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sabril&reg;: 0.5 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Vigabatrin is only available in the U.S. under a special restricted distribution program (SHARE). Under the SHARE program, only prescribers and pharmacies registered with the program are able to prescribe and distribute vigabatrin. Vigabatrin may only be dispensed to patients who are enrolled in and meet all conditions of SHARE. Contact the SHARE program at 1-888-45-SHARE.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8104264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180720.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180720.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: May be administered using an oral syringe (provided).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infantile spasms; refractory complex partial seizures not controlled by usual treatments",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional uses (not in U.S. labeling): Active management of partial or secondary generalized seizures not controlled by usual treatments",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8308547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vigabatrin may be confused with Vibativ&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and pediatric information presented combined unless significantly different.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (adults 22% to 24%; infants 17% to 45%), headache (33%), fever (adults 4% to 5%; infants 19% to 29%), fatigue (23% to 28%), dizziness (21% to 24%), irritability (adults 10%; infants 16% to 23%), sedation (adults 2% to 4%; infants 17% to 19%), insomnia (infants 10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (infants 8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (adults 7%; infants 14% to 20%), constipation (adults 6% to 8%; infants 12% to 14%), diarrhea (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (14% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Visual field constriction (&ge;30%), nystagmus (13% to 15%), blurred vision (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (infants 10% to 44%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (adults 7% to 9%; infants 46% to 51%), bronchitis (infants 30%), pharyngitis (13% to 14%), pneumonia (infants 11% to 13%), nasal congestion (infants 4% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (infants 19% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (2% to 5%), edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Memory impairment (7% to 10%), coordination impaired (7% to 9%), disturbance in attention (5% to 9%), depression (4% to 7%), lethargy (4% to 7%), seizure (infants 4% to 7%), confusion (4% to 6%), hypotonia (infants 4% to 6%), status epilepticus (2% to 6%), sensory disturbance (4% to 5%), anxiety (4%), hypoesthesia (3% to 4%), abnormal behavior (3%), abnormal thinking (3%), aggression (2%), postictal state (2%), vertigo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Contusion (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (7% to 9%), fluid retention (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (9% to 10%), appetite decreased (infants 7% to 9%), weight gain (6% to 8%), viral gastroenteritis (infants 5% to 6%), abdominal pain (3% to 5%), dyspepsia (4%), abdominal distention (2%), appetite increased  (2%), hemorrhoidal symptoms (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (4% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (8% to 10%), pain in extremity (5% to 6%), back pain (4% to 6%), hyporeflexia (4% to 5%), paresthesia (5%), weakness (5%), hyper-reflexia (4%), myalgia (3%), muscle spasms (2% to 3%), dysarthria (2%), joint swelling (2%), shoulder pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (3% to 7%), strabismus (5%), conjunctivitis (2% to 5%), eye strain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain (7% to 9%), sinusitis (infants 5% to 9%), cough (2% to 8%), sinus headache (4% to 6%), dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Candidiasis (infants 3% to 8%), influenza (3% to 5%), croup (infants 1% to 5%), thirst (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute psychosis, angioedema, cholestasis, deafness, delayed puberty, delirium, encephalopathy, facial edema, gastrointestinal hemorrhage, hypomania, laryngoedema, malignant hyperthermia, multiorgan failure, optic neuritis, pruritus, psychotic disorder, pulmonary embolism, respiratory failure, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to vigabatrin or any component of the formulation; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use has been associated with decreased hemoglobin and hematocrit; cases of significantly reduced hemoglobin (&lt;8 g/dL) and/or hematocrit (&lt;24%) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effect: Somnolence and fatigue can occur with use; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Peripheral edema independent of hypertension, heart failure, weight gain, renal or hepatic dysfunction has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Patients must be closely monitored for potential neurotoxicity (observed in animal models but not established in humans).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Peripheral neuropathy manifesting as numbness or tingling in the toes or feet, reduced distal lower limb vibration or position sensation, or progressive loss of reflexes, starting at the ankles, has been reported in adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vision loss:",
"     <b>",
"      [U.S. Boxed Warning]: Vigabatrin causes permanent vision loss in infants, children, and adults. Due to the risk of vision loss and because vigabatrin, provides an observable symptomatic benefit when it is effective, the patient who fails to show substantial clinical benefit within a short period of time after initiation of treatment (2-4 weeks for infantile spasms; &lt;3 months in adults), should be withdrawn from therapy. If in the clinical judgment of the prescriber evidence of treatment failure becomes obvious earlier in treatment, vigabatrin should be discontinued at that time. Patient response to and continued need for treatment should be periodically assessed. The onset of vision loss is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time during treatment, even after months or years. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. It is possible that vision loss can worsen despite discontinuation. Assessment of vision loss is difficult in children and the frequency and extent of vision loss in infants and children is poorly characterized. Most data are available in adult patients. Vigabatrin causes permanent bilateral concentric visual field constriction in &gt;30% of patients ranging in severity from mild to severe, including tunnel vision to within 10 degrees of visual fixation, and can result in disability. In some cases, vigabatrin can damage the central retina and may decrease visual acuity. Patient response to and continued need for vigabatrin should be periodically reassessed. In infants and children, symptoms of vision loss are unlikely to be recognized by the parent or caregiver before loss is severe. Vision loss of milder severity, although potentially unrecognized by the parent or caregiver, may still adversely affect function. Vision should be assessed to the extent possible at baseline (no later than 4 weeks after initiation), at least every 3 months during therapy and at 3-6 months after discontinuation. Once detected, vision loss is not reversible. Vigabatrin should not be used in patients with, or at high risk of, other types of irreversible vision loss unless the benefits of treatment clearly outweigh the risks. The interaction of other types of irreversible vision damage with vision damage from vigabatrin has not been well-characterized, but is likely adverse. Vigabatrin should not be used with other drugs associated with serious adverse ophthalmic effects such as retinopathy or glaucoma unless the benefits clearly outweigh the risks. The lowest dose and shortest exposure should be used that is consistent with clinical objectives. The possibility that vision loss from vigabatrin may be more common, more severe or have more severe functional consequences in infants and children than in adults cannot be excluded.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Use has been associated with an average weight gain of 3.5 kg in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric behavior: Use with caution in patients with a history of psychosis (psychotic/agitated reactions may occur more frequently), depression, or behavioral problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dose in renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: May cause an increase in seizure frequency in some patients; use with particular caution in patients with myoclonic seizures, which may be more prone to this effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly as severe sedation and confusion have been reported; consider dose and/or frequency adjustments as renal clearance may be decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MRI abnormalities: Abnormal MRI changes have been reported in some infants. Resolution of MRI changes usually occurs with discontinuation of therapy. MRI changes were not seen in older children and adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SHARE program:",
"     <b>",
"      [U.S. Boxed Warning]: In the U.S., vigabatrin is only available under a special restricted distribution program (SHARE). Under the SHARE program, only prescribers and pharmacies registered with the program are able to prescribe and distribute vigabatrin. Vigabatrin may only be dispensed to patients who are enrolled in and meet all conditions of SHARE.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Vigabatrin may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Vigabatrin may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid evening primrose (seizure threshold decreased). Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Vigabatrin crosses the placenta in humans (Tran, 1998). Birth defects have been reported following use in pregnancy and include: cardiac defects, limb defects, male genital malformations, fetal anticonvulsant syndrome, renal and ear abnormalities. Time of exposure or maternal dosage was not reported and information is not available relating to the incidence or types of these outcomes in comparison to the general epilepsy population. Visual field examinations have been conducted following in utero exposure in a limited number of children tested at &ge;6 years of age; no visual field loss was observed in 4 children and results were inconclusive in 2 others (Lawthorn, 2009; Sorri 2005). Use during pregnancy is contraindicated in Canadian product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to vigabatrin during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8107370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of vigabatrin are found in human milk (&le;4% of the weight-adjusted maternal dose based on 2 cases) (Tran, 1998). According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Use while breast-feeding is contraindicated in Canadian product labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F234003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Sabril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (50): $3381.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sabril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $6763.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic examination by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina at baseline (no later than 4 weeks after therapy initiation), periodically during therapy (every 3 months), and 3-6 months after discontinuation of therapy; assessment should include visual acuity and visual field whenever possible including mydriatic peripheral fundus examination and visual field perimetry. Observe patient for excessive sedation, especially when instituting or increasing therapy; hemoglobin and hematocrit",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sabril (AR, AT, AU, BE, BR, CH, CN, CO, CZ, DE, FR, GB, GR, HK, HN, HR, HU, IE, IT, KP, LU, NL, PL, PT, PY, SG, TR, TW, UY, ZA);",
"     </li>",
"     <li>",
"      Sabrilan (IL);",
"     </li>",
"     <li>",
"      Sabrilex (DK, ES, FI, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Irreversibly inhibits gamma-aminobutyric acid transaminase (GABA-T), increasing the levels of the inhibitory compound gamma amino butyric acid (GABA) within the brain. Duration of effect is dependent upon rate of GABA-T resynthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (rate of GABA-T resynthesis dependent): Variable (not strictly correlated to serum concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Insignificant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Tablet and oral solution are bioequivalent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Infants: 5.7 hours; Adults: 7.5 hours; Elderly: 12-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Infants: 2.5 hours; Children: 1 hour; Adults: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%, as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bar-Oz B, Nulman I, Koren G, et al, &ldquo;Anticonvulsants and Breast-Feeding: A Critical Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2000, 2(2):113-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/10937463/pubmed\" id=\"10937463\" target=\"_blank\">",
"        10937463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Challier JC, Rey E, Bintein T, et al, &ldquo;Passage of S(+) and R(-) Gamma-vinyl-GABA Across the Human Isolated Perfused Placenta,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1992, 34(2):139-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/1419475/pubmed\" id=\"1419475\" target=\"_blank\">",
"        1419475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawthom C, Smith PE, and Wild JM, &ldquo;",
"      <i>",
"       In utero",
"      </i>",
"      Exposure to Vigabatrin: No Indication of Visual Field Loss,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2009, 50(2):318-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/18616557/pubmed\" id=\"18616557\" target=\"_blank\">",
"        18616557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sabers A and Gram L, &ldquo;Newer Anticonvulsants: Comparative Review of Drug Interactions and Adverse Effects,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 60(1):23-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/10929928/pubmed\" id=\"10929928\" target=\"_blank\">",
"        10929928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorri I, Herrgard E, Viinikainen K, et al, &ldquo;Ophthalmologic and Neurologic Findings in Two Children Exposed to Vigabatrin",
"      <i>",
"       in utero",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 2005, 65(1-2):117-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/15941649/pubmed\" id=\"15941649\" target=\"_blank\">",
"        15941649",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tran A, O'Mahoney T, Rey E, et al, &ldquo;Vigabatrin: Placental Transfer",
"      <i>",
"       in vivo",
"      </i>",
"      and Excretion Into Breast Milk of the Enantiomers,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1998, 45(4):409-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/8/27783/abstract-text/9578192/pubmed\" id=\"9578192\" target=\"_blank\">",
"        9578192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10115 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-537ACF1ECA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27783=[""].join("\n");
var outline_f27_8_27783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238848\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107369\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234016\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234053\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234019\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234034\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234020\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234021\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14932727\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233994\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076373\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233980\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234385\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104264\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233996\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233995\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8308547\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234051\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233999\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233983\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233987\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234012\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233989\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234002\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234023\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107370\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234003\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324087\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233991\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234004\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233982\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233998\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/38/614?source=related_link\">",
"      Vigabatrin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=related_link\">",
"      Vigabatrin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27784="Clinical use of St. John's wort";
var content_f27_8_27784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of St. John's wort",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Robert B Saper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27784/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/8/27784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;St. John's wort (Hypericum perforatum) is a five petal yellow flower (",
"    <a class=\"graphic graphic_picture graphicRef59164 \" href=\"UTD.htm?35/38/36452\">",
"     picture 1",
"    </a>",
"    ) that has been used medicinally since antiquity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/1\">",
"     1",
"    </a>",
"    ]. It was commonly referred to as \"Fuga Demonum\" (the devil's scourge) since it was used to protect against demonic possession and \"evil spirits\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/2\">",
"     2",
"    </a>",
"    ]. One of the earliest references to the name St. John's wort is noted in a Gaelic legend from the sixth century where the missionary St. Columba carried a piece of St. John's wort because of his high regard for St. John [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/1\">",
"     1",
"    </a>",
"    ]. It is believed that the name may have been derived from the fact that the flowers bloom around June 24th, the birthday of St. John the Baptist. Wort represents the old English term for plant.",
"   </p>",
"   <p>",
"    St. John's wort has been utilized mainly for its antidepressant activity, but also for its purported antiinflammatory and wound healing properties [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/3\">",
"     3",
"    </a>",
"    ]. The 2007 National Health Interview Survey found a large decrease in St. John's wort use by adults in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2002, St. John's wort was the sixth most popular natural product in the United States, used by 2.2 percent of American adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/5\">",
"     5",
"    </a>",
"    ]. In 2007, St. John's wort was not among the 20 most commonly used dietary supplements [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/4\">",
"     4",
"    </a>",
"    ]. This decrease may reflect the public's response to interim news reports of negative clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] and potentially harmful interactions with prescription drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/9-22\">",
"     9-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of compounds isolated from St. John's wort possess pharmacologic activity. Naphthodianthrones (hypericin, pseudohypericin, protohypericin, protopseudohypericin, and cyclopseudohypericin), flavonoids (quercetin, rutin, and luteolin), hyperforin, several amino acids, and tannins have been isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Neuropsychiatric activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of in vitro studies of St. John's wort have attempted to define its neuropharmacology. Hyperforin and hypericin have been studied most extensively. Hypericin was originally thought to be the major active component for St. John's wort in depression; however, it is now believed that hyperforin and related compounds are mostly responsible for St. John's wort's effect on mood.",
"   </p>",
"   <p>",
"    Hyperforin extracts have been shown to modulate neurotransmitter levels including serotonin, norepinephrine, and dopamine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This may be in part from inhibition of neurotransmitter uptake. Other studies have found that hypericum extract possesses a weak catechol-O-methyl transferase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/26\">",
"     26",
"    </a>",
"    ], and the hypericum extract LI 160 causes 50 percent inhibition of serotonin uptake by rat synaptosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/27\">",
"     27",
"    </a>",
"    ]. The latter occurred only at relatively high concentrations.",
"   </p>",
"   <p>",
"    St. John's wort standardized extract LI 160 is capable of decreasing cell surface 5-HT receptors. LI 160 also suppresses the release of interleukin-6 (IL-6), which induces the release of corticotropin releasing hormone (implicated in depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. St. John's wort extracts also have been shown to inhibit binding at the muscarinic cholinergic receptor (mAchR), 5HT, and norepinephrine uptake sites, but only at high concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/30\">",
"     30",
"    </a>",
"    ]. Extracts may have further effects upon melatonin secretion, biological rhythms, and sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/31\">",
"     31",
"    </a>",
"    ]. Others have hypothesized that hypericum extract increases dopamine turnover resulting in an increased concentration of dopamine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/32\">",
"     32",
"    </a>",
"    ]. MAO inhibition was formerly believed to be a mechanism of St. John's wort, but animal studies suggest that MAO inhibition is minimal and likely not clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antiviral and antibacterial activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro antiviral activity has been reported against murine cytomegalovirus, parainfluenza 3 virus, Sindbis virus, vesicular stomatitis virus, and equine infectious anemia virus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In addition, hypericin and pseudohypericin inhibit herpes simplex types 1 and 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/3\">",
"     3",
"    </a>",
"    ]. Other studies have indicated immunologic and potential clinical benefits of utilizing hypericin in vitro for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Hypericin and pseudohypericin display activity against retroviruses in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypericin also has antibacterial activity against gram-positive and gram-negative organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/3,41\">",
"     3,41",
"    </a>",
"    ]. These effects may explain the use of St. John's wort for wound healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other activities associated with St. John's wort extracts include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experimentally induced inflammation and leukocyte infiltration is suppressed in mice using a topical extract of St. John's wort&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Flavonoid fractions (mainly quercetin) have analgesic activity in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The tannin component of the plant probably exerts an astringent action that may contribute to its purported effectiveness as a wound healing agent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral and topical administration of hypericin has been utilized for the treatment of vitiligo and as an antiinflammatory and antiulcerogenic agent, due most likely to the component amentoflavone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS/INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;United States (US) popularity for St. John's wort in depression was generated from publicity due to a 1996 British Medical Journal paper [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/44\">",
"     44",
"    </a>",
"    ]. The authors performed a meta-analysis of 23 clinical trials performed predominantly in Europe (20 double-blind, 2 open, and 1 single blind) involving 1757 patients with mild to moderate depressive disorders taking St. John's wort, tricyclic antidepressants,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    placebo. Trials lasted up to 12 weeks, with doses of St. John's wort ranging from 300 to 1000 mg daily. The effect size of St. John's wort extracts were significantly superior to placebo (odds ratio 2.67, 95% CI 1.78-4.01) and similar to tricyclic antidepressants including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    (odds ratio 1.10, 95% CI 0.93-1.31). Adverse effects from St. John's wort were not mentioned specifically in this meta-analysis; only numbers of side effects and incidence were noted. Critics of the study note the use of small doses of standard medications and the short duration of most of the studies as methodological weaknesses. In addition, no trials using selective serotonin reuptake inhibitors (SSRIs) were included.",
"   </p>",
"   <p>",
"    A report from the Agency for Health Care Policy and Research agreed that St. John's wort is more effective than placebo for the short-term treatment of mild depressive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/45\">",
"     45",
"    </a>",
"    ]. However, these findings were tempered by the methodological quality of the trials and possibility of publication bias favoring positive trials.",
"   </p>",
"   <p>",
"    Additional studies in Europe published since the above meta-analysis have also demonstrated the efficacy of St. John's wort in treating depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standardized extract of St. John's wort Ze 117 (500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in a multicenter randomized double-blind trial of 240 patients with mild to moderate depression in Germany [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/46\">",
"       46",
"      </a>",
"      ]. Sixty percent of the St. John's wort group compared to 40 percent of the fluoxetine group responded based upon Hamilton Depression scores (p &lt;0.005). A trend for fewer side effects in the St. John's wort group was also found. A limitation of this trial was the absence of a placebo control arm.",
"     </li>",
"     <li>",
"      Standardized St. John's wort extract WS 5570 (300 mg three times daily) for six weeks was compared to placebo in a double-blind randomized trial of 375 French outpatients with mild to moderate depression [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/47\">",
"       47",
"      </a>",
"      ]. The St. John's wort extract was significantly more effective than placebo in reducing Hamilton Depression scores. Adverse events in the two groups were similar and minor.",
"     </li>",
"     <li>",
"      A six-week multicenter randomized trial of 251 outpatients in Germany with moderate to severe acute major depression compared standardized St. John's wort extract WS 5570 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients were treated for two weeks with either WS 5570 300 mg three times daily or paroxetine 20 mg daily; the dose in nonresponders was increased to WS 5570 600 mg three times daily or paroxetine 40 mg daily. The trial was designed as a noninferiority study and found that Hamilton depression scores declined by at least as much in patients treated with WS 5570 as with paroxetine (57 versus 45 percent decrease). There was no placebo arm in this study. The authors felt that a placebo control would be unethical given the inclusion of patients with severe depression.",
"     </li>",
"     <li>",
"      A six-week randomized trial in 332 adults with mild or moderate depression compared WS 5570 600 mg daily, 600 mg twice daily, and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/49\">",
"       49",
"      </a>",
"      ]. There were larger decreases in Hamilton depression scores (the primary outcome measure of the study) in patients treated with once daily or twice daily WS 5570 than with placebo (11.6 and 10.8 versus 6.0 points, respectively).",
"     </li>",
"     <li>",
"      A six-week randomized trial in 388 patients with moderate depression compared STW 3-VI 900 mg daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      20 mg daily, and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/50\">",
"       50",
"      </a>",
"      ]. Decreases in Hamilton depression scores with STW 3-VI and citalopram were similar and superior to placebo (11.6 and 11.5 versus 9, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, at least four randomized double-blind placebo-controlled trials performed in the US have not found similarly positive results for St. John's wort in depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 200 adult outpatients with major depression were randomly assigned to receive St. John's wort extract (900",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for four weeks, increased to 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      if no response) or placebo for eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/6\">",
"       6",
"      </a>",
"      ]. There were no significant differences between the two groups in any outcome measures. Advocates of St. John's wort have criticized this study noting that the subject population was a homogeneous group of chronic (&gt;two years) more severely depressed patients receiving care from tertiary care clinics in academic medical centers.",
"     </li>",
"     <li>",
"      A study sponsored by the NIH National Center for Complementary and Alternative Medicine randomly assigned 340 adult outpatients with moderate to severe depression to St. John's wort (900 to 1500 mg, standardized to the hypericin component),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      (50 to 100 mg), or placebo for eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/7\">",
"       7",
"      </a>",
"      ]. Neither St. John's Wort nor sertraline was significantly more effective than placebo in reducing Hamilton Depression scores.",
"      <br/>",
"      <br/>",
"      A major criticism of this study was that it was difficult to interpret the St. John's wort data given that the sertraline arm did not show benefit over placebo as anticipated. Restricting the maximum dose of sertraline to 100 mg may have been one reason for limited efficacy in this group. Others noted that the St. John's wort preparation was standardized to hypericin whereas hyperforin is now considered more important for St. John's wort's antidepressant effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12-week study in 135 adults with moderate depression compared St. John's wort extract (LI-160 900",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      20 mg daily, and placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/8\">",
"       8",
"      </a>",
"      ]. The primary endpoint was Hamilton depression score at the end of the study. This was lower with LI-160 than fluoxetine, but not significantly lower than with placebo (10.2 versus 13.3 and 12.6, respectively). This study may have been underpowered as it did not reach recruitment goals, but it was stopped early by the sponsors based on problems with recruitment and an interim analysis.",
"     </li>",
"     <li>",
"      A 12-week trial randomly assigned 73 patients with minor depression to St. John&rsquo;s wort,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , or placebo. Neither St. John&rsquo;s Wort nor citalopram showed significant differences compared to placebo. Both St. John&rsquo;s Wort and citalopram contributed to significant adverse events during the study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there are data from European trials that support the efficacy of standardized extracts of St. John's wort in the short-term treatment of mild to moderate depression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/52\">",
"     52",
"    </a>",
"    ]. However, these results have not been replicated in the US. Reasons for this discrepancy are uncertain but may include differences in patients enrolled, lack of concealment of treatment allocation, or the herbal preparations studied. The lack of large confirmatory studies in the US and poor regulation of dietary supplement quality lead us to suggest not treating depression with St. John's wort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Somatoform disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two placebo-controlled trials, each lasting six weeks, found St. John's wort (300 mg twice daily) was efficacious for treating somatoform disorders independent of any existing depression, and was also well tolerated and safe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In one study involving 149 patients, more patients improved with St. John's wort than placebo (81 versus 50 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/53\">",
"     53",
"    </a>",
"    ]. Relative responses were similar in another study of 173 patients (45 versus 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299916679\">",
"    <span class=\"h2\">",
"     Menopausal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized placebo-controlled trials suggest St. John&rsquo;s wort may reduce the frequency and severity of hot flashes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In one study involving 100 women randomized to St. John&rsquo;s wort extract (standardized to 0.2 percent hypericin) or placebo, there were significant reductions in hot flash frequency, duration, and severity at eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/56\">",
"     56",
"    </a>",
"    ]. However, weaknesses in these trials included small sample size, incomplete characterization of herbal product, and no assessment of the effectiveness of patient blinding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Attention deficit/hyperactivity disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial in 54 children and adolescents with attention",
"    <span class=\"nowrap\">",
"     deficit/hyperactivity",
"    </span>",
"    disorder found no benefits on attention or hyperactivity with St. John's wort 300 mg (standardized to 0.3 percent hypericin) three times daily for eight weeks, compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/57\">",
"     57",
"    </a>",
"    ]. Adverse events were also similar with St. John's wort or placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HIV Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase I trial of 30 HIV-infected patients with CD4 counts less than 350",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    evaluated the safety and antiretroviral activity of hypericin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/58\">",
"     58",
"    </a>",
"    ]. Subjects received intravenous hypericin (0.25 or 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight twice weekly or 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times weekly) or oral hypericin (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily). Treatment was discontinued in 16 of 30 (53 percent) before completing eight weeks because of moderate or severe phototoxicity. Only two patients completed 24 weeks of therapy. No demonstrable antiretroviral activity at the doses tested was noted. Analyses of HIV p24 antigen levels, culture titers, and RNA levels showed no significant changes. Median CD4 cell counts decreased during the study. The authors concluded that the hypericin therapy utilized was too toxic to allow evaluation of any antiretroviral potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15401335\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials found no benefit of St. John&rsquo;s wort for smoking cessation, in comparison to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15401419\">",
"    <span class=\"h2\">",
"     Irritable bowel syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 12 week randomized trial of St. John&rsquo;s wort (900 mg daily) versus placebo in 70 patients with irritable bowel syndrome showed greater benefit for placebo compared to St. John&rsquo;s wort for self-reported bowel symptom score [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of the adverse effects of St. John's wort in clinical studies found that dropout and adverse effects rates in patients receiving St. John's wort were comparable to placebo, lower than tricyclic antidepressants, and slightly lower than SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/9,62\">",
"     9,62",
"    </a>",
"    ]. The most common drug reactions included gastrointestinal symptoms,",
"    <span class=\"nowrap\">",
"     dizziness/confusion,",
"    </span>",
"    <span class=\"nowrap\">",
"     tiredness/sedation,",
"    </span>",
"    photosensitivity, dry mouth, urinary frequency, anorgasmia, and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of photosensitivity have been reported in patients taking oral St. John's wort [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/58,63,64\">",
"     58,63,64",
"    </a>",
"    ]. These involved a delayed",
"    <span class=\"nowrap\">",
"     hypersensitivity/photodermatitis",
"    </span>",
"    following ingestion of herbal tea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/63\">",
"     63",
"    </a>",
"    ] and reversible photosensitivity after taking 240 mg of hypericum extract daily for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/64\">",
"     64",
"    </a>",
"    ]. Erythematous lesions in light-exposed areas developed but cleared with discontinuation. Limited phototoxicity of oral extracts was seen in a randomized placebo-controlled multiple cross-over study of 13 subjects receiving hypericum extract at various doses who were exposed to solar and UVA light before and four hours after drug intake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/65\">",
"     65",
"    </a>",
"    ]. External use of hypericum extracts have been noted in several anecdotal reports to lead to second degree burns, resulting in scarring, after exposure to direct sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An in vitro study noted that high concentrations of St. John's wort had adverse effects upon oocytes and was mutagenic to sperm cells, leading to concerns that use may lead to decreased fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of St. John's wort should be avoided during pregnancy and lactation since there are inadequate data to demonstrate its safety. Some in vitro uterotonic effects have been reported in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/68\">",
"     68",
"    </a>",
"    ]. No large scale observational studies in humans have been conducted to evaluate the safety of St. John&rsquo;s wort in pregnancy. One small study, however, compared birth outcomes between 54 pregnancies exposed to St. John&rsquo;s wort, 54 exposed to conventional anti-depressants, and 54 healthy non-exposed women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/69\">",
"     69",
"    </a>",
"    ]. Major fetal malformations were found in 5.3, 4.3, and 0 percent, respectively (p = 0.26).",
"   </p>",
"   <p>",
"    The authors of a literature review of herb use in the perioperative period suggested that, because of the various drug interactions with St. John's wort, it should be discontinued at least five days prior to a planned operative procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HERB-DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interactions between St. John's wort and medications are the most common source of adverse effects related to St. John's wort [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/9\">",
"     9",
"    </a>",
"    ]. Demonstrated adverse interactions between St. John's wort and certain medications were among the first herb-drug interactions reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/10\">",
"     10",
"    </a>",
"    ]. These reports contributed to the growing recognition among clinicians of the potential for adverse herb-drug interactions and the need to ask all patients about nonprescription herb and supplement use. Specific interactions of St. John&rsquo;s wort with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p>",
"    Treatment failures with a wide variety of agents including anticoagulants, antiretrovirals, antifungals, immunosuppressive agents, narcotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and hormonal contraceptives have been associated with the concomitant use of St. John's wort due to significant induction of CYP 1A2, 2C19, 2C9, and 3A4, as well as intestinal",
"    <span class=\"nowrap\">",
"     P-glycoprotein/MDR-1",
"    </span>",
"    drug transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/12-22,71-76\">",
"     12-22,71-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of St. John's wort should be avoided in combination with other antidepressants until a definitive mechanism of action is elucidated to avoid the potential for the serotonin syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/77\">",
"     77",
"    </a>",
"    ]. Several cases of serotonin excess (agitation, hyperthermia, diaphoresis, tachycardia, and neuromuscular disturbances including rigidity) also have been reported in elderly individuals taking St. John's wort and SSRIs together [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/78\">",
"     78",
"    </a>",
"    ]. It is prudent to have a three- to seven-day wash-out period prior to switching from an SSRI to St. John&rsquo;s wort, and a three-week wash-out period prior to switching from an MAO inhibitor to St. John's wort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H4#H4\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Switching between SSRIs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link&amp;anchor=H11#H11\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Switching to or from MAOIs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examples of significant interactions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in healthy volunteers, peak plasma levels of the protease inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      were reduced more than 50 percent when St. John's wort was taken concomitantly [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/10\">",
"       10",
"      </a>",
"      ]. A reduction of this magnitude would be sufficient to cause treatment failure in an HIV-infected patient receiving highly active antiretroviral therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link&amp;anchor=H33#H33\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\", section on 'Abacavir-lamivudine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There was a report of two cases of acute heart transplant rejection from a reduction in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      levels due to concomitant St. John's wort&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are case reports of breakthrough bleeding and undesired pregnancy in women taking oral contraceptive pills, presumably due to lowering of ethinylestradiol concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Avoidance of foods containing tyramine while taking St. John's wort is considered unnecessary due to St. John's wort's limited MAO inhibitory activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/26,79\">",
"     26,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies of St. John's wort utilized extracts standardized to either 0.3 percent hypericin or 5 percent hyperforin in a dosage of 300 to 400 mg three times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/6,7,44,45\">",
"     6,7,44,45",
"    </a>",
"    ]. Caution should be employed with long-term use of hypericum extracts due to a lack of studies beyond 8 to 12 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BRAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good Manufacturing Practices for the dietary supplement industry have been established by the United States Food and Drug Administration (FDA) and were phased in from 2008 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27784/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .) However, no studies have been published after 2010 to assess the impact of these new regulations on standardization and quality. The resultant uncertainty in the quality of products is another reason arguing against recommending St. John&rsquo;s wort in the US.",
"   </p>",
"   <p>",
"    Patients who choose to use St. John's wort can use brands that have passed specified quality criteria by independent commercial laboratories (",
"    <a class=\"graphic graphic_table graphicRef82438 \" href=\"UTD.htm?36/38/37483\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who choose to use St. John's wort should be counseled and cautioned regarding evidence of efficacy and safety, the variability and lack of regulation in St. John's wort products in the United States, and the potential for herb-drug interactions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      European studies of well-defined standardized extracts of St. John's wort in the short-term treatment of mild-to-moderate depression suggest it is more effective than placebo and equivalent to tricyclic antidepressants and SSRIs. However, studies in the US do not support its efficacy. The reasons for this discrepancy are unclear but may include differences in study design, such as concealment of treatment allocation, or in the herbal preparations studied. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the inconsistent evidence for efficacy, and the lack of regulated standardized products proven to be efficacious, we suggest not treating depression with St. John's wort&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      St. John's wort has the potential for multiple herb-drug interactions through induction of the CYP3A4 and P-glycoprotein systems. Concurrent use of St. John's wort and medications metabolized by these systems should be avoided. Additionally, there have been reports of serotonin syndrome in patients taking St. John's wort concurrently with SSRI antidepressants. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Herb-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The variability in available products' quality and contents due to regulatory issues in the US is a limitation to their clinical utility. For patients who choose to use St. John's wort, they should select products that meet specific quality criteria according to independent laboratory testing (",
"      <a class=\"graphic graphic_table graphicRef82438 \" href=\"UTD.htm?36/38/37483\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Brand'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/1\">",
"      Hobbs C. St. John's wort--ancient herbal protector. Pharm Hist 1990; 32:166.",
"     </a>",
"    </li>",
"    <li>",
"     Pratt A. Wild Flowers, Society for Promoting Christian Knowledge, London 1853.",
"    </li>",
"    <li>",
"     St. John's Wort. In: Lawrence Review of Natural Products, Facts and Comparisons, St. Louis 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/4\">",
"      Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/5\">",
"      Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/6\">",
"      Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/7\">",
"      Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002; 287:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/8\">",
"      Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005; 25:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/9\">",
"      Kn&uuml;ppel L, Linde K. Adverse effects of St. John's Wort: a systematic review. J Clin Psychiatry 2004; 65:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/10\">",
"      Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000; 355:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/11\">",
"      Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/12\">",
"      Johne A, Brockm&ouml;ller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/13\">",
"      Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/14\">",
"      Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/15\">",
"      Smith PF, Bullock JM, Booker BM, et al. Induction of imatinib metabolism by hypericum perforatum. Blood 2004; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/16\">",
"      Mueller SC, Uehleke B, Woehling H, et al. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/17\">",
"      Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/18\">",
"      Tannergren C, Engman H, Knutson L, et al. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/19\">",
"      Hebert MF, Park JM, Chen YL, et al. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/20\">",
"      Eich-H&ouml;chli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St. John's Wort - a case report. Pharmacopsychiatry 2003; 36:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/21\">",
"      Mills E, Montori VM, Wu P, et al. Interaction of St John's wort with conventional drugs: systematic review of clinical trials. BMJ 2004; 329:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/22\">",
"      Nieminen TH, Hagelberg NM, Saari TI, et al. St John's wort greatly reduces the concentrations of oral oxycodone. Eur J Pain 2010; 14:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/23\">",
"      Bennett DA Jr, Phun L, Polk JF, et al. Neuropharmacology of St. John's Wort (Hypericum). Ann Pharmacother 1998; 32:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/24\">",
"      M&uuml;ller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl 1:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/25\">",
"      Singer A, Wonnemann M, M&uuml;ller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999; 290:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/26\">",
"      Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/27\">",
"      Perovic S, M&uuml;ller WE. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 1995; 45:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/28\">",
"      M&uuml;ller WE, Rossol R. Effects of hypericum extract on the expression of serotonin receptors. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/29\">",
"      Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/30\">",
"      Muller, WE, Schafer, C. Johanniskraut: in-vitro Studie uber Hypericum-Extrakt, Hypericin und Kampferol. Deutsche Apotheker Zeitung 1996; 136:1015.",
"     </a>",
"    </li>",
"    <li>",
"     Demisch, L, Nispel, J, Sielaff, T, et al. Influence of subchronic Hyperforat administration on melatonin production. Arbeitsgemeinschaft fur Neuro und Psychopharmakologie-symposium Abstracts, Nurnberg 1991.",
"    </li>",
"    <li>",
"     Winterhof H, Butterweck V, Nahrstedt A, et al. Phytopharmaka in Forschung unf klinischer Anwendung, Steinkopff Verlag GmbH and Co, Darmstadt, Germany 1995. p.S39.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/33\">",
"      Negrash AK. Comparative study of chemotherapeutic and pharmacological properties of antimicrobial preparation from common St. John's Wort. Fitonsidy Mater Soveshch 1969; :198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/34\">",
"      Lopez-Bazzocchi I, Hudson JB, Towers GH. Antiviral activity of the photoactive plant pigment hypericin. Photochem Photobiol 1991; 54:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/35\">",
"      Wood, S, Huffman, J, Weber, N, et al. Antiviral activity of naturally occurring anthraquinones and anthraquinone derivatives. Planta Medica 1990; 56:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/36\">",
"      Carpenter S, Kraus GA. Photosensitization is required for inactivation of equine infectious anemia virus by hypericin. Photochem Photobiol 1991; 53:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/37\">",
"      Lavie G, Valentine F, Levin B, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci U S A 1989; 86:5963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/38\">",
"      Schinazi RF, Chu CK, Babu JR, et al. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res 1990; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/39\">",
"      Hudson JB, Lopez-Bazzocchi I, Towers GH. Antiviral activities of hypericin. Antiviral Res 1991; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/40\">",
"      Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A 1988; 85:5230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/41\">",
"      Gaind, KN, Ganjoo, TN. Antibacterial principle of Hypericum perforatum Linn. Indian J Pharm 1959; 21:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/42\">",
"      Shipochliev T, Dimitrov A, Aleksandrova E. [Anti-inflammatory action of a group of plant extracts]. Vet Med Nauki 1981; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/43\">",
"      Vasilchenko, EA. Analgesic action of flavonoids of Rhododendron luteum Sweet, Hypericum perforatum L., Lespedeza bicolor Turcz. And L. hedysaroides (Pall.) Kitag Rastit Resur 1986; 22:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/44\">",
"      Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313:253.",
"     </a>",
"    </li>",
"    <li>",
"     Treatment of Depression&ndash;Newer Pharmacotherapies. Summary, Evidence Report/Technology Assessment: Number 7, March 1999. Agency for Health Care Policy and Research, Rockville, MD. Available at: www.ahcpr.gov/clinic/epcsums/deprsumm.htm (Accessed on August 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/46\">",
"      Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. Pharmacopsychiatry 2001; 34 Suppl 1:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/47\">",
"      Lecrubier Y, Clerc G, Didi R, Kieser M. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/48\">",
"      Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005; 330:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/49\">",
"      Kasper S, Anghelescu IG, Szegedi A, et al. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006; 4:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/50\">",
"      Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006; 39:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/51\">",
"      Rapaport MH, Nierenberg AA, Howland R, et al. The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res 2011; 45:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/52\">",
"      Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; :CD000448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/53\">",
"      M&uuml;ller T, Mannel M, Murck H, Rahlfs VW. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004; 66:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/54\">",
"      Volz HP, Murck H, Kasper S, M&ouml;ller HJ. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 2002; 164:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/55\">",
"      Al-Akoum M, Maunsell E, Verreault R, et al. Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: a randomized pilot trial. Menopause 2009; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/56\">",
"      Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause 2010; 17:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/57\">",
"      Weber W, Vander Stoep A, McCarty RL, et al. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA 2008; 299:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/58\">",
"      Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/59\">",
"      Parsons A, Ingram J, Inglis J, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend 2009; 102:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/60\">",
"      Sood A, Ebbert JO, Prasad K, et al. A randomized clinical trial of St. John's wort for smoking cessation. J Altern Complement Med 2010; 16:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/61\">",
"      Saito YA, Rey E, Almazar-Elder AE, et al. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol 2010; 105:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/62\">",
"      Kasper S, Gastpar M, M&ouml;ller HJ, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol 2010; 25:204.",
"     </a>",
"    </li>",
"    <li>",
"     Newall CA, Anderson LA, Phillipson JD. Herbal medicines: A guide for health-care professionals, The Pharmaceutical Press, London 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/64\">",
"      Golsch S, Vocks E, Rakoski J, et al. [Reversible increase in photosensitivity to UV-B caused by St. John's wort extract]. Hautarzt 1997; 48:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/65\">",
"      Brockm&ouml;ller J, Reum T, Bauer S, et al. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30 Suppl 2:94.",
"     </a>",
"    </li>",
"    <li>",
"     Upton, R (ed). American Herbal Pharmacopoeia and Therapeutic Compendium. St. John's Wort Hypericum perforatum 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/67\">",
"      Ondrizek RR, Chan PJ, Patton WC, King A. An alternative medicine study of herbal effects on the penetration of zona-free hamster oocytes and the integrity of sperm deoxyribonucleic acid. Fertil Steril 1999; 71:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/68\">",
"      K��nchev K, Liutskanov D, Arsenov L. [Comparative studies of plans for controlling American foulbrood in public aviaries]. Vet Med Nauki 1981; 18:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/69\">",
"      Moretti ME, Maxson A, Hanna F, Koren G. Evaluating the safety of St. John's Wort in human pregnancy. Reprod Toxicol 2009; 28:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/70\">",
"      Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/71\">",
"      Gordon RY, Becker DJ, Rader DJ. Reduced efficacy of rosuvastatin by St. John's Wort. Am J Med 2009; 122:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/72\">",
"      Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/73\">",
"      Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97:7500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/74\">",
"      Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/75\">",
"      Mannel M. Drug interactions with St John's wort : mechanisms and clinical implications. Drug Saf 2004; 27:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/76\">",
"      Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/77\">",
"      Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/78\">",
"      Lantz MS, Buchalter E, Giambanco V. St. John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27784/abstract/79\">",
"      Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 1994; 7 Suppl 1:S57.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topics/NEWS/2007/NEW01657.html (Accessed on October 09, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1391 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27784=[""].join("\n");
var outline_f27_8_27784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Neuropsychiatric activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antiviral and antibacterial activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL TRIALS/INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Somatoform disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299916679\">",
"      Menopausal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Attention deficit/hyperactivity disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15401335\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15401419\">",
"      Irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HERB-DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BRAND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1391\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1391|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/38/36452\" title=\"picture 1\">",
"      St Johns wort",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1391|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/38/37483\" title=\"table 1\">",
"      St Johns wort quality criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27785="Treatment of relapsed or refractory peripheral T cell lymphoma";
var content_f27_8_27785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsed or refractory peripheral T cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Eric Jacobsen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27785/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/8/27785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. Among these, in decreasing frequency of occurrence, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS)",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type (ALCL)",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma (AITL)",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Adult T cell leukemia-lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"     <li>",
"      Mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of relapsed or refractory nodal PTCL will be reviewed here. The initial treatment of PTCL is discussed separately, as are the following PTCL subtypes (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult T cell leukemia-lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=see_link\">",
"       \"Treatment and prognosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"       \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"       \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=see_link\">",
"       \"Treatment of extranodal NK/T cell lymphoma, nasal type\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, diagnosis, and prognosis of PTCLs are presented elsewhere as is the treatment of newly diagnosed PTCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION OF SUSPECTED RESISTANCE OR RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial therapy, patients are followed at routine intervals to monitor for treatment-related complications and progression. At these visits, patients are evaluated with a history, physical examination, blood work, and imaging studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Patient follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive disease (PD) can present with systemic B symptoms (ie, fever, night sweats, weight loss), cytopenias, the development of an extranodal mass, or as the symptomatic or asymptomatic enlargement of the lymph nodes, liver, or spleen. By definition, PD reflects the appearance of any new lesion, a 50 percent increase in the longest diameter of a previously identified lesion, or",
"    <span class=\"nowrap\">",
"     new/recurrent",
"    </span>",
"    involvement of the bone marrow (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"UTD.htm?29/27/30140\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When relapse is suspected, a biopsy of the involved lymph node or mass is recommended to confirm relapse and evaluate for a potential change in histology. Infrequently, patients with PTCL can develop a B cell lymphoma at the time of relapse, resulting in a change in preferred therapy. Also, other conditions, including inflammatory disorders, can mimic relapsed lymphoma. Once relapse is confirmed, the patient should undergo a staging evaluation with a physical examination, imaging studies, and a bone marrow biopsy (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Refractory (resistant) disease is defined as those patients who fail to obtain an at least partial response with initial treatment as determined by an at least 50 percent decrease in lesion size with no new lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED/REFRACTORY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262318756\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, most patients undergoing treatment for PTCL will either not achieve remission or will relapse. There is a paucity of data regarding the treatment of these patients. The general approach has been to administer a second-line combination chemotherapy regimen with the hope of attaining a complete remission (CR). Patients who respond to these therapies should be offered autologous or allogeneic hematopoietic cell transplantation (HCT) given the potential for long-term disease-free survival after these procedures and the lack of long-term responders after chemotherapy alone.",
"   </p>",
"   <p>",
"    Treatment of patients who are not transplant candidates, who fail to respond to second line chemotherapy regimens, or who relapse after transplant is generally palliative. Data supporting the use of most agents are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard therapy for patients with PTCL. As such, patients should be strongly encouraged to participate in a clinical trial. At present, no single chemotherapy regimen is clearly superior to any other. Outside the context of a clinical trial, the selection of treatment should be based upon expected toxicities, patient comorbidities, and convenience. For most patients with relapsed or refractory PTCL, we suggest administration of a traditional chemotherapy regimen rather than the use of a novel agent. This preference is based upon the higher response rates seen with traditional agents and the knowledge that patients who achieve a complete response have a chance of long-term survival with transplantation. Novel agents are typically reserved for subsequent relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Traditional regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are transplant candidates may respond to traditional regimens used for aggressive lymphoma such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ICE (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DHAP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      ESHAP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , methyl-prednisolone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Published experience is largely limited to case reports of patients with PTCL and phase II trials in a heterogeneous population of patients with aggressive NHLs. Patients with PTCL have comprised a minority of the patients included in trials of these regimens for aggressive NHL. With these regimens, overall response rates for patients with PTCL are approximately 40 to 50 percent. These trials are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2362416\">",
"    <span class=\"h3\">",
"     Novel agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, we suggest the administration of a traditional combination chemotherapy regimen for most patients with relapsed or refractory PTCL, particularly if they are candidates for either allogeneic or autologous hematopoietic cell transplantation. Novel agents are typically reserved for subsequent relapses or patients receiving treatment with non-curative intent. Our choice among the novel agents is generally guided by the specific subtype of PTCL and the toxicity profiles of the agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with relapsed or refractory anaplastic large cell lymphoma (ALCL), we suggest the use of brentuximab over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4185630\">",
"       'Brentuximab'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients with relapsed or refractory angioimmunoblastic T cell lymphoma (AITL), we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H195153770\">",
"       'Romidepsin'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In all other settings, the choice between these agents should be based upon the patient's ability to tolerate anticipated toxicities.&nbsp;For instance,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      may be preferred in patients with a history of cardiac arrhythmia (particularly ventricular arrhythmia). In contrast,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      may be preferred in patients who would not be expected to tolerate mucositis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The studies that support the use of these agents in PTCL are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4185630\">",
"    <span class=\"h4\">",
"     Brentuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"     Brentuximab vedotin",
"    </a>",
"    (SGN-35) is an immunotoxin with a CD-30 directed antibody linked to the antitubulin agent monomethyl auristatin E (MMAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/7\">",
"     7",
"    </a>",
"    ]. Brentuximab vedotin was granted accelerated approval by the US Food and Drug Administration for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"     brentuximab vedotin",
"    </a>",
"    in this patient population come from two single arm, prospective trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase I trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      in 45 patients with CD30 positive hematopoietic cancers relapsed or refractory after a median of three prior therapies, there were 11 complete remissions (CR), six partial remissions, and 19 cases with stable disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/9\">",
"       9",
"      </a>",
"      ]. The two patients with anaplastic large-cell lymphoma attained a complete remission. Side effects were generally mild with the most common being fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy.",
"     </li>",
"     <li>",
"      In a phase II multicenter trial, 58 patients with relapsed or refractory ALCL were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"       brentuximab vedotin",
"      </a>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for up to 16 cycles) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/10\">",
"       10",
"      </a>",
"      ]. The overall response rate was 86 percent (57 percent complete) with median times to objective and complete response of 6 and 12 weeks, respectively. The median duration of response following CR was 13 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      side effects were neutropenia (21 percent), thrombocytopenia (10 percent), and peripheral sensory neuropathy (10 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies confirm the efficacy of this agent in patients with ALCL. Infusion reactions are uncommon, but anaphylaxis has been reported. Progressive multifocal leukoencephalopathy is a rare complication of brentuximab treatment and typically presents with subacute neurologic deficits, which may include altered mental status, visual symptoms, weakness, ataxia, and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H582577#H582577\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Brentuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43064?source=see_link&amp;anchor=H582252#H582252\">",
"     \"Neurologic complications of cancer treatment with biologic agents\", section on 'Brentuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Pralatrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials of the novel antifolate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"     pralatrexate",
"    </a>",
"    have demonstrated encouraging response rates in PTCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase I trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      in 20 patients with relapsed or refractory lymphoma included four patients with T cell lymphoma, all of whom attained a complete response [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/12\">",
"       12",
"      </a>",
"      ]. An expansion phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial of pralatrexate in 20 additional patients with PTCL reported 10 responses, 9 of which were complete. The drug demonstrated activity across histologies. The primary toxicities were mucositis and thrombocytopenia, although these were abrogated by the introduction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      and vitamin B12 supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An international, open label phase II registration trial (the PROPEL trial) evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"       pralatrexate",
"      </a>",
"      in 115 heavily pretreated patients with PTCL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients received pralatrexate 30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for six of every seven weeks along with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      1 mg by mouth daily and vitamin B12 injections monthly. Patients were heavily pretreated with a median of three prior therapies (range 1 to 12) and 16 percent of patients had failed a prior autologous hematopoietic cell transplant. Approximately 60 percent of patients were refractory after their most recent therapy and approximately 25 percent had never responded to any chemotherapy. The following outcomes were reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The overall response rate (ORR) was 29 percent with 18 percent partial responses (PR) and 11 percent complete response (CR) or CR, unconfirmed. Twenty-one patients (19 percent) had stable disease.",
"     </li>",
"     <li>",
"      The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were thrombocytopenia (33 percent) and mucosal inflammation (22 percent).",
"     </li>",
"     <li>",
"      Responses were generally rapid with 63 percent of patients responding after one cycle. The median time on therapy for all responders was 186 days and the median duration of response was 10 months. The median overall and progression free survival times were 14.5 and 3.5 months, respectively.",
"     </li>",
"     <li>",
"      Responses were observed across all histologic subtypes, although patients with angioimmunoblastic T cell lymphoma (AITL) were less likely to respond than patients with other common PTCL subtypes. Interestingly, the likelihood of response did not seem to correlate with the number of prior therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/43/29366?source=see_link\">",
"     Pralatrexate",
"    </a>",
"    is approved for use in relapsed or refractory PTCL by the United States Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195153770\">",
"    <span class=\"h4\">",
"     Romidepsin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"     Romidepsin",
"    </a>",
"    is a histone deacetylase inhibitor that has demonstrated responses in relapsed or refractory PTCL in phase II trials. It has not been directly compared with other treatments in a randomized fashion. Romidepsin was granted accelerated approval by the US Food and Drug Administration for the treatment of patients with PTCL who have received at least one prior therapy. This approval was based upon two phase II trials that demonstrated responses in 25 to 38 percent of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      (14",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15 of a 28-day cycle) in 45 patients with relapsed or refractory PTCL who had received a median of three prior therapies showed an overall response rate (ORR) of 38 percent (eight complete, nine partial) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/16\">",
"       16",
"      </a>",
"      ]. The median duration of response was nine months (range 2 to 74 months). Although the most frequent adverse effects were generally mild and included nausea (51 percent), fatigue (41 percent), thrombocytopenia (47 percent), and decreased absolute granulocyte count (45 percent), one patient, who had a history of significant coronary artery disease, died while in complete remission.",
"     </li>",
"     <li>",
"      An international phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"       romidepsin",
"      </a>",
"      (14",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15 of a 28-day cycle) in 130 patients with relapsed or refractory PTCL who had received a median of two prior therapies showed an ORR of 25 percent (15 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/17\">",
"       17",
"      </a>",
"      ]. Responses were similar in all subtypes of PTCL. Objective responses were seen at a median of two months and complete responses were seen at a median of 3.7 months. With a median follow-up of 13 months, the median duration of response was 17 months. Response duration was longest for those with AITL for whom the median duration of response had not been reached and some patients were still in complete remission after 34 months. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included thrombocytopenia (25 percent), neutropenia (20 percent), anemia (10 percent), and fatigue (8 percent). Serious infections were also seen in 19 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several treatment-emergent morphological changes in ECGs (including T-wave and ST-segment changes) have been reported in clinical studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    in cutaneous T cell lymphomas, but have not been shown to be clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In patients with congenital long QT syndrome, patients with a history of significant cardiovascular disease, and patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation, appropriate cardiovascular monitoring precautions should be considered, such as the monitoring of electrolytes and ECGs at baseline and periodically during treatment. All patients should have potassium and magnesium levels in the normal range before drug administration. There is no required monitoring of ECGs in patients who do not have the above risk factors. Romidepsin is metabolized by CYP3A4. Co-administration of strong CYP3A4 inhibitors or potent CYP3A4 inducers should be avoided, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H52#H52\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Histone deacetylase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (allo-HCT) and autologous HCT (auto-HCT) administered after response to second-line chemotherapy offer a chance of long-term survival. Patients who achieve a complete remission (CR) before transplant have a higher chance of long-term survival. The efficacy varies with PTCL subtype. For fit patients with relapsed disease, allo-HCT is generally preferred to auto-HCT due to its superior efficacy in uncontrolled prospective trials and retrospective studies. Auto-HCT is generally reserved for patients with relapsed or refractory ALK positive anaplastic large cell lymphoma (ALCL).",
"   </p>",
"   <p>",
"    A benefit from HCT has been suggested in retrospective analyses and small prospective trials. As an example, a population-based study evaluated the outcomes of 208 adults with relapsed, refractory PTCL, excluding ALK+ ALCL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/21\">",
"     21",
"    </a>",
"    ]. At a median follow-up of four years, the median overall survival was seven months. Median survival was significantly higher for those patients who were able to proceed with HCT (47 versus 5 months).",
"   </p>",
"   <p>",
"    For medically fit patients with relapsed or refractory PTCL other than ALK positive anaplastic large cell lymphoma, we suggest the use of combination chemotherapy. Patients who respond to salvage chemotherapy should be offered allo-HCT or auto-HCT rather than observation alone. We favor allo-HCT for patients who have received an autologous HCT previously, those who require multiple salvage chemotherapy regimens to achieve remission, and for patients with tumor histology other than ALCL, peripheral T cell lymphoma not otherwise specified, or angioimmunoblastic T cell lymphoma. Reduced intensity allo-HCT may be considered for older patients who cannot tolerate myeloablative conditioning.",
"   </p>",
"   <p>",
"    For patients with relapsed or refractory ALK positive ALCL, we suggest treatment with combination chemotherapy followed by auto-HCT. Chemotherapy followed by allogeneic HCT would be an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Allogeneic HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (allo-HCT) has been studied in a selective group of patients with relapsed or refractory PTCL. Rates of overall survival at five years post-transplant are approximately 50 to 60 percent, with non-relapse mortality (NRM) rates of 20 to 25 percent.",
"   </p>",
"   <p>",
"    Small, uncontrolled prospective trials and retrospective analyses have investigated the use of allo-HCT in PTCL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An uncontrolled prospective trial of 17 patients with relapsed (15 patients) or refractory PTCL who underwent salvage chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      followed by a reduced intensity allo-HCT from a sibling (16 patients) or matched unrelated donor reported five-year progression-free and overall survival rates were 49 and 54 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/22\">",
"       22",
"      </a>",
"      ]. At a median follow-up from enrollment of 28 months, 14 patients were still alive, two patients had died of progressive disease, and one had died with sepsis.",
"     </li>",
"     <li>",
"      An uncontrolled prospective trial investigated the use of a nonmyeloablative preparative regimen (2 Gy total body irradiation plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      ) followed by allo-HCT in 17 patients with T cell or NK cell NHL that was",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      (14 patients) or in first complete remission [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/25\">",
"       25",
"      </a>",
"      ]. After a median follow-up of 3.3 years, estimated rates of overall and progression-free survival at three years were 59 and 53 percent, respectively. Estimated rates of non-relapse mortality and relapse at three years were 19 and 26 percent, respectively.",
"     </li>",
"     <li>",
"      A single-center retrospective analysis included 52 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      (42 patients) or newly diagnosed (10 patients) PTCL or advanced mycosis",
"      <span class=\"nowrap\">",
"       fungoides/S&eacute;zary",
"      </span>",
"      syndrome who underwent myeloablative (60 percent) or reduced intensity allogeneic HCT and reported rates of progression-free and overall survival at three years of 30 and 41 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/27\">",
"       27",
"      </a>",
"      ]. When compared with reduced intensity regimens, myeloablative regimens were associated with higher non-relapse mortality (36 versus 14 percent at three years) and lower relapse rates, resulting in similar survival. When compared with predominantly extranodal histologies (eg,",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, cutaneous lymphomas), patients with a predominantly nodal histologies had superior progression-free survival (45 versus 6 percent) and overall survival (52 versus 23 percent) at three years. At a median follow-up of 49 months, there appeared to be a plateau in the survival curves suggesting possible cure of a subset of patients.",
"     </li>",
"     <li>",
"      A retrospective study of 45 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      (34 patients) or newly diagnosed (11 patients) angioimmunoblastic T cell lymphoma (AITL) treated with myeloablative (25 patients) or reduced intensity allo-HCT reported rates of five-year progression free and overall survival of 57 and 64 percent, respectively. Again, the non-relapse mortality rates were 29 and 24 percent for patients who received myeloablative or reduced intensity allo-HCT, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that some patients with relapsed or refractory PTCL who undergo allo-HCT will achieve long-term disease control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Autologous HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation (auto-HCT) is frequently incorporated into the initial treatment of patients with PTCL as consolidation therapy after initial combination chemotherapy. Auto-HCT appears to be less effective in the treatment of relapsed or refractory disease, except perhaps for patients with ALK positive anaplastic large cell lymphoma (ALCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/28\">",
"     28",
"    </a>",
"    ]. When compared with patients transplanted in first complete remission (CR), overall and progression free survival rates are significantly lower when auto-HCT is performed on patients in subsequent CR, partial remission (PR), or those with progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Consolidation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are examples of the prospective and retrospective studies that have investigated auto-HCT for relapsed or refractory PTCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective series of 28 patients transplanted for relapsed PTCL reported a three-year OS rate of 69 percent. A subset analysis of patients with ALCL found a three-year overall survival (OS) rate of 86 percent. ALK positive patients had an event-free survival of 100 percent at three years compared to zero percent in ALK negative cases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest retrospective analysis, performed by the European Group for Blood and Marrow Transplantation (EBMT), evaluated 64 adult and pediatric patients (median age 25 years) who underwent auto-HCT for ALCL in CR (47 percent), PR (28 percent), or with more",
"      <span class=\"nowrap\">",
"       advanced/chemotherapy",
"      </span>",
"      refractory disease (25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/30\">",
"       30",
"      </a>",
"      ]. Eighty-one percent of the patients were conditioned with chemotherapy alone and 75 percent received marrow stem cells. Relapse or progression was noted in one of the 15 patients transplanted in first CR, 6 of 15 patients transplanted in a subsequent CR, 6 of 18 patients transplanted in PR, and 14 of 16 patients transplanted in a refractory or relapsed disease state. Actuarial OS at 10 years was 70 percent. Multivariate analysis revealed superior outcomes for patients with the following characteristics: CR at transplant, younger age, absence of B symptoms, and lack of extranodal disease.",
"     </li>",
"     <li>",
"      In a trial of 15 patients with ALK negative ALCL undergoing auto-HCT, 13 patients relapsed after transplant and the median progression-free survival was 12 weeks with a median OS of 72 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is no standard therapy for patients with relapsed or refractory PTCL. As such, patients should be strongly encouraged to participate in a clinical trial. A decision to refer the patient for a clinical trial should be determined by the overall clinical situation and the enthusiasm of the patient for palliative measures. Ongoing trials are evaluating traditional chemotherapy agents in new combinations for the treatment of relapsed or refractory PTCL. The following sections describe some of the newer agents being studied in PTCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the role of the anti-CD52 monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    alone or in combination with chemotherapy for the treatment of PTCL. CD52 is expressed by approximately half of PTCLs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/32\">",
"     32",
"    </a>",
"    ]. Overall response rates (ORRs) have ranged from 30 to 75 percent. Infectious complications are common, but appear to be less frequent when a lower dose and duration of alemtuzumab is used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pilot study of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (30 mg three times weekly for up to 12 weeks) in 14 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      PTCL, reported an ORR of 36 percent with three complete (CR) and two partial (PR) responses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/33\">",
"       33",
"      </a>",
"      ]. The median duration of response was not reported but the CRs lasted 2, 6, and 12 months. Notably, six patients experienced cytomegalovirus (CMV) reactivation and five patients died of infectious complications. Only one of the 14 patients completed the full 12 weeks of therapy.",
"     </li>",
"     <li>",
"      A preliminary report of a phase II trial of single agent low dose subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (10 mg three times weekly for four weeks) in 10 patients with heavily pretreated relapsed T cell lymphoma (6 with PTCL and 4 with CTCL), reported an ORR of 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/34\">",
"       34",
"      </a>",
"      ]. Within the PTCL subset, there were two CRs and one PR with a median duration of response of seven months. One out of 10 patients experienced CMV reactivation and none died of infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have examined the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in combination with CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) for the treatment of PTCL. Substantial toxicity, especially infectious complications, raises questions about the utility of this regimen despite impressive response rates and duration of response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of standard dose CHOP plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (30 mg IV on day 1) was terminated early due to infectious complications after only 20 of the planned 43 patients were accrued [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/35\">",
"       35",
"      </a>",
"      ]. The complete response rate was 65 percent with a one-year event free survival of 43 percent. Unfortunately, 25 percent of the patients experienced CMV reactivation with three patients developing invasive CMV disease.",
"     </li>",
"     <li>",
"      Another trial of standard dose CHOP with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (30 mg SC added on day -1) reported an ORR of 75 percent with 17 CRs and 1 PR [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/36\">",
"       36",
"      </a>",
"      ]. The median duration of response was 11 months. Several significant infections occurred including Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia.",
"     </li>",
"     <li>",
"      A third trial of standard dose CHOP every 14 days (CHOP-14) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      (30 mg SC given on days 1, 5, and 10) in 20 patients with PTCL reported an ORR of 90 percent with 12 CRs, one unconfirmed CR, and five PRs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/37\">",
"       37",
"      </a>",
"      ]. At a median follow-up of 29 months, the median failure free survival was 10 months and the median OS was 27 months. Despite the routine use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) as well as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      , cotrimoxazole, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis, infectious complications were substantial. Seven of 20 patients developed CMV reactivation and one developed invasive CMV disease. Eight patients were hospitalized for fever and neutropenia. One patient died in CR five months after treatment due to sepsis complicating an extensive varicella zoster infection. Three patients developed an Epstein Barr virus (EBV)-related lymphoproliferative disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of CHOP plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in PTCL is undefined. The regimen has significant activity but also worrisome infectious toxicity. The early discontinuation of the trial that investigated CHOP with intravenous alemtuzumab suggests that this combination is not feasible. Similarly, the CHOP-14 regimen with three doses of alemtuzumab per cycle seems prohibitively toxic. It is now well known that subcutaneous alemtuzumab is better tolerated than the intravenous formulation. A randomized trial of CHOP administered every three weeks with or without subcutaneous alemtuzumab is ongoing and should better define the role of this combination in PTCL.",
"   </p>",
"   <p>",
"    There are additional reports of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    being used in combination with other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    , but a paucity of systematized data precludes any meaningful comment about the future of such combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Denileukin diftitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    is a recombinant interleukin-2 (IL-2)-diphtheria toxin fusion protein that is approved by the United States FDA for patients with persistent or recurrent cutaneous T cell lymphoma (CTCL) expressing the CD25 component of the IL-2 receptor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Denileukin diftitox'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A phase II trial of single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    in patients with relapsed or refractory PTCL reported an overall response rate (ORR) of 61 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/38\">",
"     38",
"    </a>",
"    ]. Toxicities included hypoalbuminemia (79 percent); transaminitis (60 percent); flu like symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an infusion reaction (85 percent); and vascular leak syndrome (25 percent). More data are needed on the efficacy and toxicity of denileukin diftitox in patients with PTCL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bortezomib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small prospective trials have evaluated the proteosome inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    for the treatment of patients with PTCL. The primary toxicity of bortezomib in this setting appears to be similar to that seen in patients with multiple myeloma and mainly consists of neuropathy and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Bortezomib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1,4, 8, and 11 of a 21-day cycle) in 15 patients with",
"      <span class=\"nowrap\">",
"       relapsed/refractory",
"      </span>",
"      PTCL (2 patients) or cutaneous T cell lymphoma (CTCL) reported an overall response rate (ORR) of 67 percent with two complete (CR) and six partial remissions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/39\">",
"       39",
"      </a>",
"      ]. Of the two patients with PTCL, one attained a CR. The responses were durable, lasting on average 7 to 14 months.",
"     </li>",
"     <li>",
"      A phase I study evaluated the use of standard dose CHOP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      in 13 patients with advanced, aggressive T cell or",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/40\">",
"       40",
"      </a>",
"      ]. No dose limiting toxicities were observed up to the maximal dose of bortezomib of 1.6",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      The CR rate was 62 percent. No data were given for progression-free or overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    and CHOP is feasible in PTCL although it is impossible to say at present whether it improves outcomes over CHOP alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25702125\">",
"    <span class=\"h2\">",
"     Crizotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     Crizotinib",
"    </a>",
"    is a small molecule inhibitor of the ALK tyrosine kinase that has demonstrated activity in a subset of patients with non-small cell lung cancer. A case report of two patients with multiply relapsed ALK positive anaplastic large cell lymphoma (ALCL) reported complete responses to after treatment with crizotinib (250 mg twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/41\">",
"     41",
"    </a>",
"    ]. Further studies of this agent in ALK positive ALCL are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Histone deacetylase (HDAC) inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given their role in the treatment of cutaneous T cell lymphoma, several histone deacetylase (HDAC) inhibitors have been evaluated for use in PTCL. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    , belinostat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/2/3110?source=see_link\">",
"     romidepsin",
"    </a>",
"    (depsipeptide), and LBH589 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Of these, romidepsin has been approved by the US Food and Drug Administration for the treatment of relapsed or refractory PTCL. Other HDAC inhibitors are still undergoing investigation. (See",
"    <a class=\"local\" href=\"#H195153770\">",
"     'Romidepsin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Preliminary results from a phase II trial of belinostat (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 to 5 of a 21-day cycle) in 11 evaluable patients with PTCL reported two complete responses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27785/abstract/43\">",
"     43",
"    </a>",
"    ]. Seven patients experienced severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    adverse events including peripheral edema, apraxia, adynamic ileus, pruritus, rash, thrombocytopenia, and infection. One patient died of ventricular fibrillation six days after discontinuing treatment. There have been concerns regarding the potential for HDAC inhibitors to prolong the QT interval and result in cardiac arrhythmias.",
"   </p>",
"   <p>",
"    The role of these agents in PTCL remains to be defined. We await the final results of additional studies that are ongoing. Toxicity with HDAC inhibitors is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Romidepsin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas in adults. The initial treatment of PTCL generally consists of combination chemotherapy with or without consolidation autologous hematopoietic cell transplantation (HCT) or radiation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"       \"Initial treatment of peripheral T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When relapse is suspected, a biopsy of the involved lymph node or mass is strongly suggested to confirm relapse and to evaluate for a potential change in histology. Infrequently, patients with PTCL can develop a B cell lymphoma at the time of relapse. Many inflammatory conditions can also have a clinical and radiographic appearance suggestive of recurrent lymphoma. Once relapse is confirmed, the patient should undergo a staging evaluation with a physical examination, imaging studies, and a bone marrow biopsy (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation of suspected resistance or relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no general consensus regarding the optimal treatment regimen for these patients and all patients should be encouraged to participate in clinical trials. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We offer the following suggestions for patients who are not candidates for or choose not to participate in clinical trials. Patients are generally treated with combination chemotherapy regimens in an attempt to achieve a complete remission. At present, no single chemotherapy regimen is clearly superior to any other. Outside the context of a clinical trial the selection of treatment should be based upon expected toxicities, patient comorbidities, and convenience. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For medically fit patients with relapsed or refractory PTCL other than ALK positive anaplastic large cell lymphoma (ALCL), we suggest the use of combination chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HCT) or autologous HCT (auto-HCT) rather than observation alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We favor allo-HCT for patients who have received an auto-HCT previously, those who require multiple salvage chemotherapy regimens to achieve remission, and for patients with tumor histology other than anaplastic large cell lymphoma, peripheral T cell lymphoma not otherwise specified, or angioimmunoblastic T cell lymphoma. Reduced intensity allo-HCT may be considered for older patients who cannot tolerate myeloablative conditioning. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Allogeneic HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with relapsed or refractory ALK positive anaplastic large cell lymphoma, we suggest treatment with combination chemotherapy followed by auto-HCT rather than observation alone after chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Chemotherapy followed by allogeneic HCT would be an acceptable alternative for young, fit, motivated individuals. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Autologous HCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/1\">",
"      Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14 Suppl 1:i5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/2\">",
"      Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/3\">",
"      Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/4\">",
"      Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010; 21:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/5\">",
"      Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/6\">",
"      L&oacute;pez A, Guti&eacute;rrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008; 80:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/7\">",
"      Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010; 16:888.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf (Accessed on August 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/9\">",
"      Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/10\">",
"      Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190.",
"     </a>",
"    </li>",
"    <li>",
"     file://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed on January 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/12\">",
"      O'Connor OA, Hamlin PA, Portlock C, et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007; 139:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/13\">",
"      O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009; 27:4357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/14\">",
"      O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/15\">",
"      Malik SM, Liu K, Qiang X, et al. Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2010; 16:4921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/16\">",
"      Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117:5827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/17\">",
"      Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/18\">",
"      Munster PN, Rubin EH, Van Belle S, et al. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009; 15:7077.",
"     </a>",
"    </li>",
"    <li>",
"     Romidepsin: Treatment of Cutaneous T-cell Lymphoma (CTCL), including Relief of Pruritus, in Patients who have Received at Least One Prior Systemic Therapy. Sponsor's Background Package for the Oncologic Drugs Advisory Committee Meeting Scheduled for September 2, 2009. (Available at file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180633.pdf, accessed February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/20\">",
"      Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/21\">",
"      Mak V, Connors JM, Klasa R, et al. Survival of peripheral T cell lymphomas patients following relapse: Spectrum of disease and rare long-term survivors (abstract 96). Blood 2011; 118:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/22\">",
"      Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/23\">",
"      Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci&eacute;t&eacute; Francaise de Greffe de Mo&euml;lle et de Th&eacute;rapie Cellulaire. J Clin Oncol 2008; 26:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/24\">",
"      Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/25\">",
"      Shustov AR, Gooley TA, Sandmaier BM, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 2010; 150:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/26\">",
"      Dodero A, Spina F, Narni F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/27\">",
"      Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/28\">",
"      Rodr&iacute;guez J, Caballero MD, Guti&eacute;rrez A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/29\">",
"      Jagasia M, Morgan D, Goodman S, et al. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 2004; 45:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/30\">",
"      Fanin R, Ruiz de Elvira MC, Sperotto A, et al. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/31\">",
"      Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/32\">",
"      Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12:7174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/33\">",
"      Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103:2920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/34\">",
"      Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 2005; 90:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/35\">",
"      Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007; 60:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/36\">",
"      Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/37\">",
"      Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011; 22:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/38\">",
"      Dang NH, Pro B, Hagemeister FB, et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007; 136:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/39\">",
"      Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/40\">",
"      Lee J, Suh C, Kang HJ, et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 2008; 19:2079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/41\">",
"      Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011; 364:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/42\">",
"      Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109.",
"     </a>",
"    </li>",
"    <li>",
"     Advani R, Hymes K, Pohlman B, et al. Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study. American Society of Hematology 2007 Annual Meeting, abstract 3453.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27785/abstract/44\">",
"      Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14:4500.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4742 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27785=[""].join("\n");
var outline_f27_8_27785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION OF SUSPECTED RESISTANCE OR RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF RELAPSED/REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262318756\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Traditional regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2362416\">",
"      - Novel agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4185630\">",
"      Brentuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pralatrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H195153770\">",
"      Romidepsin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Allogeneic HCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Autologous HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Denileukin diftitox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bortezomib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25702125\">",
"      Crizotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Histone deacetylase (HDAC) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/27/30140\" title=\"table 1\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 2\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43064?source=related_link\">",
"      Neurologic complications of cancer treatment with biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30281?source=related_link\">",
"      Treatment and prognosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12457?source=related_link\">",
"      Treatment of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27786="Antithrombotic therapy for percutaneous coronary intervention: General use";
var content_f27_8_27786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombotic therapy for percutaneous coronary intervention: General use",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/8/27786/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/8/27786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stents are usually thrombogenic because they are generally made of stainless steel or cobalt chrome alloys, most of which predispose to thrombosis. Early studies utilizing older stent deployment techniques showed that acute (usually less than 24 hours) or subacute (five to six days) thrombosis occurred in approximately 18 percent of cases. When it develops, stent thrombosis occurs within the first week after deployment in over 80 percent of cases with bare metal stents and within the first month in over 35 percent of cases with drug eluting stents. The continuous use of dual antiplatelet therapy for one year or longer in patients with drug eluting stents is now recommended to decrease the rate of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aggressive antithrombotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , platelet P2Y12 receptor blockers, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, and parenteral anticoagulants is used to decrease the risk of stent thrombosis. Recommendations for the use of these agents in stable patients before and within the first few days of stent placement will be the primary focus of the discussion here. Details of the clinical trials supporting these recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will also briefly address the use of oral antiplatelet therapy in patients who receive balloon angioplasty without stenting.",
"   </p>",
"   <p>",
"    The discussion of the long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to prevent late and very late stent thrombosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antithrombotic therapy in the setting of acute coronary syndromes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASPIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is given to all patients undergoing coronary stenting to reduce the likelihood of early complications. This recommendation is based primarily upon data from randomized trials, of aspirin or aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    versus placebo, in patients undergoing PTCA prior to the development of stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H3#H3\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    300 to 325 mg, preferably given at least two hours before the procedure, is given to patients not taking aspirin and those on a maintenance dose of &lt;325 mg.",
"   </p>",
"   <p>",
"    For",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    allergic patients, we usually recommend desensitization therapy before the stent procedure. In circumstances wherein this approach is not possible, an IV GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonist is recommended during the PCI procedure. Patients who cannot tolerate long-term aspirin are usually treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H36#H36\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subject of",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy appears to reduce the incidence of late stent thrombosis, since aspirin cessation has been associated with this complication in both bare metal and drug-eluting stents. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are not good data to recommend the higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and, especially for patients with an increased risk of serious bleeding (for example, those receiving chronic anticoagulation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ), a reduced dose of aspirin may be appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     P2Y12 RECEPTOR BLOCKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet P2Y12 receptor blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , and cangrelor achieve their antiplatelet effect by blocking the binding of ADP to a specific platelet receptor P2Y12 that activates Gi, thereby inhibiting adenylyl cyclase and platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/1\">",
"     1",
"    </a>",
"    ]. Clopidogrel and ticlopidine have been extensively evaluated, both during and after the procedure and then when also given as pretreatment, in patients undergoing elective stent implantation. Prasugrel and ticagrelor have been used primarily in the setting of acute coronary syndromes. Cangrelor is an intravenous agent that has been compared to clopidogrel in the periprocedural period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With primary PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is given in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to all patients undergoing elective coronary artery stenting to reduce the risk of stent thrombosis. The efficacy of these agents has been demonstrated in numerous randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H4#H4\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     Ticlopidine",
"    </a>",
"    was the first widely used thienopyridine for the prevention of stent thrombosis. However, hematologic side effects limit its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Ticlopidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenia, which can be severe, occurs in approximately 1.0 to 2.4 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . It usually appears during the first three months of treatment and requires immediate discontinuation of the drug. A less frequent problem is fatal agranulocytosis with thrombocytopenia, which has been seen as early as three to four weeks after starting ticlopidine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link&amp;anchor=H12#H12\">",
"     \"Drug-induced neutropenia and agranulocytosis\", section on 'Ticlopidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A less frequent but even more serious complication of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    is thrombotic thrombocytopenia purpura-hemolytic uremic syndrome (TTP-HUS). The reported incidence is 1 case in 1600 to 1 in 4800 when the drug is used after cardiac stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. All cases occur within 12 weeks, and 75 percent between 3 and 12 weeks. Treatment includes discontinuation of the drug and plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H112796012#H112796012\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Ticlopidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the seriousness of these complications, it is essential to obtain a complete blood count with platelet count and white cell differential every two weeks for four months after starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other side effects include rash (2 percent), diarrhea (3 percent), dyspepsia, hepatic dysfunction, and the development of bronchiolitis obliterans organizing pneumonia (BOOP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    because it appears to be as effective, is a once-a-day medication, and has a lower incidence of side effects, particularly far fewer hematologic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Timing and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing and dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy vary with the clinical setting. The data supporting the use of clopidogrel therapy in patients with a non-ST elevation acute coronary syndrome (ACS) who are selected for an invasive strategy or those with ST elevation myocardial infarction (STEMI) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H13#H13\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H21914160#H21914160\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal timing and dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients with stable coronary artery disease has not been well studied. Recommendations come from observations made from early trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    use, limited evidence from trials which enrolled patients with stable angina, and from trials of patients with ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CREDO trial of patients with stable angina found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (300 mg loading dose) had to be given at least six hours before PCI to achieve a reduction in complications related to stent thrombosis (death, myocardial infarction, or urgent target vessel revascularization) (",
"    <a class=\"graphic graphic_figure graphicRef67652 \" href=\"UTD.htm?4/9/4254\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/6\">",
"     6",
"    </a>",
"    ]. A subsequent subgroup analysis showed that the benefit of the clopidogrel loading dose was first significant 15 hours before PCI and was greatest at 24 hours before PCI (",
"    <a class=\"graphic graphic_figure graphicRef79395 \" href=\"UTD.htm?32/47/33533\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The PRAGUE-8 (stable angina) and ARMYDA-5 PRELOAD (61 percent stable angina) trials demonstrated equivalent efficacy and safety with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    600 mg given either before (mean of 19 and 6 hours respectively in the two trials) or after elective coronary arteriography (CAG) but before PCI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on all available evidence, we recommend a loading dose of 600 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    preferably starting 24 hours or more, but at least two hours, before scheduled or anticipated PCI in most patients.",
"   </p>",
"   <p>",
"    However, for those stable patients in whom pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    cannot be accomplished or who have a low likelihood of needing PCI, withholding clopidogrel until after CAG is reasonable. It is reasonable to withhold clopidogrel until after the results of CAG are known also in patients who have a high likelihood of needing coronary artery bypass grafting, such as those with strongly positive non-invasive tests or those with known severe coronary artery disease from prior CAG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible efficacy of higher loading doses, such as 900 or even 1200 mg, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have not received the recommended dose and timing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    before PCI as described above, consideration can be given to the addition of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy, based upon its known immediate antiplatelet effect and its beneficial role in studies of its use in patients who received PTCA, such as EPISTENT and ESPRIT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is 75 mg daily, with the duration determined, in part, by the type of stent placed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts have suggested augmenting the 75 mg daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    dose, particularly for patients who demonstrate minimal inhibition of platelet aggregation. The issue of when to test for clopidogrel nonresponse and resistance, and what to do about it if found, is controversial. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Patients already taking clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether patients who are receiving chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy require an additional loading dose before PCI to reduce periprocedural events has not been well studied. Two randomized trials that included both stable and acute coronary syndrome patients taking clopidogrel for at least seven days have attempted to address this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the RELOAD trial, 166 patients were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      reloading with 900, 600, or 300 mg [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/8\">",
"       8",
"      </a>",
"      ]. The primary outcome was the relative change compared to baseline in the inhibition or residual platelet function at four hours after dosing. The 900 mg dose produced a significantly greater reduction in platelet function compared to either of the lower doses.",
"     </li>",
"     <li>",
"      In the ARMYDA-4 RELOAD trial, 503 patients were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg or placebo loading four to eight hours before PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/9\">",
"       9",
"      </a>",
"      ]. There was no significant difference in the primary combined endpoint of the 30 day incidence of death, MI, or target vessel revascularization (6.7 versus 8.8 percent respectively). Almost all of the events were attributable to a rise in biomarker. There were no episodes of major bleeding in either group. The clinical relevance of this finding remains to be determined. In the subset of patients with acute coronary syndromes (ACS) there was a significant benefit (6.4 versus 16.3 percent; OR 0.34, 95% CI 0.32-0.90).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our experts feel the evidence is not robust enough to make a strong suggestion for or against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    reloading. They suggest clopidogrel reloading with 600 of clopidogrel in patients on long term clopidogrel therapy either who undergo PCI at the time of ACS or who are at high risk of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Possible CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;An occasional stable patient may need coronary artery bypass graft surgery (CABG) soon after catheterization. The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline on CABG recommended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    should be discontinued for at least five days before CABG, based on the recognition of an increase in perioperative bleeding in patients taking clopidogrel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/10\">",
"     10",
"    </a>",
"    ]. The management of platelet P2Y12 receptor blocker therapy in patients needing urgent or emergent CABG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H21914160#H21914160\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo PCI with stenting must be properly informed of the importance of compliance to recommendations made regarding long term dual antiplatelet therapy. Most patients will be discharged on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 mg daily for a variable minimum duration depending on stent type and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    75 to 100 mg daily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clopidogrel resistance/nonresponse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general subject of",
"    <span class=\"nowrap\">",
"     resistance/nonresponse",
"    </span>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adverse interaction with proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal bleeding is a risk of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , particularly in the time around placement of an intracoronary stent when other antithrombotic therapy may be used. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Gastrointestinal bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Proton pump inhibitors (PPI) have been recommended for the prevention of gastrointestinal bleeding in patients at high risk for clinically important gastrointestinal bleeding. However, reports in 2008 and 2009 have raised concerns that some, but not necessarily all, PPIs interfere with the ability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to inhibit platelet function and thereby increase the likelihood of coronary artery stent thrombosis, myocardial infarction, or cardiovascular death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971641#H5971641\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H8#H8\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Primary prevention of aspirin induced GI bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H12#H12\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Proton pump inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our recommendations for the use of PPIs in patients on dual antiplatelet therapy, including those patients who have undergone PCI, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=see_link&amp;anchor=H5971648#H5971648\">",
"     \"Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intracoronary radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to intracoronary radiation (brachytherapy) have become less of a concern since the availability of drug-eluting stents has led to the near disappearance of brachytherapy procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H23#H23\">",
"     \"Intracoronary stent restenosis\", section on 'Repeat stenting in bare-metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who do receive intracoronary radiation, the FDA recommends antiplatelet therapy for a minimum of six months after brachytherapy (and one year may be preferred) and for at least one year if a new stent is implanted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/11\">",
"     11",
"    </a>",
"    ]. The FDA also suggested avoidance of placement of new stents when brachytherapy is used. Potential indications for new stent implantation are evident dissection or marked elastic recoil either within or at the margins of the restenotic stent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=see_link&amp;anchor=H16#H16\">",
"     \"Use of intracoronary radiation to prevent restenosis\", section on 'Prolonged dual antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     TTP-HUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is a less common cause of",
"    <span class=\"nowrap\">",
"     TTP/HUS",
"    </span>",
"    than is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . Although phase III clinical trials reported no incidence of TTP-HUS with clopidogrel, its subsequent use among more than three million individuals has been associated with the development of TTP-HUS in 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/12\">",
"     12",
"    </a>",
"    ]. Unlike TTP-HUS induced by ticlopidine, the disorder typically occurred within two weeks of the initiation of clopidogrel. Ten of the 11 patients responded to plasma exchange, but two required 20 or more exchanges for disease resolution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    develops in one to four percent of patients and typically appears between 5 and 10 days after initiation of therapy. The most common presentation is an erythematous, macular, pruritic rash, which typically begins on the face, chest, or abdomen, then spreads and becomes confluent (",
"    <a class=\"graphic graphic_picture graphicRef83637 \" href=\"UTD.htm?31/23/32118\">",
"     picture 1",
"    </a>",
"    ). Given the importance of prolonged dual antiplatelet therapy in patients who receive intracoronary stents, those who develop an apparent hypersensitivity to clopidogrel need the issue addressed in a timely manner. We suggest referring these patients to a specialist in the care of patients with medication allergies. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26232?source=see_link\">",
"     \"Hypersensitivity reactions to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142865664\">",
"    <span class=\"h3\">",
"     Prasugrel and ticagrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     Prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    have not been evaluated in patients with stable disease undergoing PCI. Their role in patients with acute coronary syndromes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With primary PCI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142865718\">",
"    <span class=\"h3\">",
"     Cangrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cangrelor is an intravenous P2Y12 receptor blocker that has been compared to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or placebo in three trials that have included patients with stable coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Cangrelor'",
"    </a>",
"    .) Two of these trials found no significant benefit to cangrelor. The largest trial, CHAMPION PHOENIX, found a 22 percent relative risk reduction (and a 1.2 percent absolute risk reduction) in the primary composite end point (death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours) comparing cangrelor to clopidogrel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/13\">",
"     13",
"    </a>",
"    ]. Limitations of the trial include suboptimal timing (about 37 percent received the drug during or after the procedure) and dosing (about 25 percent received a 300 rather than a 600 mg loading dose) of clopidogrel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, the primary composite end point benefit was driven by a reduction in the rates of periprocedural myocardial infarction.",
"   </p>",
"   <p>",
"    Cangrelor is not available in the US or Europe for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and thienopyridine produces significantly better outcomes than aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . In the STARS trial, for example, 1653 patients who received a",
"    <strong>",
"     stent",
"    </strong>",
"    were randomly assigned to aspirin, aspirin plus warfarin, or aspirin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/15\">",
"     15",
"    </a>",
"    ]. At 30 days, the incidence of the primary end point of events reflecting stent thrombosis (death, emergency CABG, Q wave MI, or angiographically evident thrombosis) was significantly lower with aspirin plus ticlopidine (0.5 versus 2.7 with aspirin plus warfarin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H6#H6\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Efficacy and safety'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H7#H7\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Timing and dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients who require both long term anticoagulant and antiplatelet therapies is discussed below. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Patients who require warfarin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17964165\">",
"    <span class=\"h1\">",
"     GP IIB/IIIA INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients who undergo PCI with stent implantation varies with the clinical setting. The trial data supporting the following conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H11#H11\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'GP IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Elective stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing elective PCI who are at low to intermediate risk (stable native vessel coronary disease and no major comorbidities), the ISAR-REACT trial found no benefit from GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy at 30 days or one year in patients pretreated with high-dose (600 mg)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    at least two hours before the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A similar lack of benefit in lower risk patients was noted in a subgroup analysis from the ESPRIT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    therapy has replaced the combination of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in such patients. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Bivalirudin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a result, many interventionalists limit the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors during elective PCI to higher-risk patients, those who have not receive adequate pretreatment with oral antiplatelet therapy, or those with a suboptimal angiographic result. The timing and dose of these drugs is presented separately (",
"    <a class=\"graphic graphic_table graphicRef64612 \" href=\"UTD.htm?34/50/35628\">",
"     table 1",
"    </a>",
"    ). The optimal duration of treatment with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors for those patients who have received adequate pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has not been well studied. In such patients, experts vary between discontinuation after PCI to as long as recommended in the package inserts for each drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients with acute coronary syndromes scheduled to undergo PCI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H29#H29\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'GP IIb/IIIa inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H24#H24\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk for bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a major bleeding complication after PCI in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is mildly increased in those who have received GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors. The risk is particularly increased in older adults, women, or those with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link&amp;anchor=H39#H39\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to gastrointestinal bleeding occurring after PCI are discussed below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Gastrointestinal bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     Abciximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    , are associated with an increased risk of thrombocytopenia. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In terms of the choice of drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    has no persistent advantage over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    for nonemergent stenting. The initial benefit is probably due to more complete platelet inhibition with the regimens used. Tirofiban and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    are substantially less expensive than abciximab and their use is associated with lower hospital and 30-day costs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    for elective PCI and for more urgent PCI in non-ST elevation ACS because of lower cost and comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    and because the optimal dosing regimen to achieve the desired level of early platelet inhibition is more clearly defined [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/20\">",
"     20",
"    </a>",
"    ] than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When PCI for ACS is delayed,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    using current dosing regimens is a reasonable alternative. The relative efficacy of high-dose tirofiban, used in the EVEREST and ADVANCE trials [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    should be clarified by the TENACITY trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PARENTERAL ANTICOAGULANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For stable patients undergoing percutaneous coronary intervention (PCI), we recommend anticoagulant therapy with either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    . Based upon limited evidence, we suggest all stable patients be pretreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and thienopyridine. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of giving intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) before PCI to prevent intracoronary or device related thrombosis was initiated when percutaneous transluminal coronary angioplasty was the procedure of choice (ie, before the stent era) and prior to the routine use of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a thienopyridine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/24\">",
"     24",
"    </a>",
"    ]. The rationale for anticoagulation is that the procedure is associated with factors that predispose to thrombosis: stasis within the coronary artery and catheters and exposure of the clotting elements of the blood to an injured endothelium and to catheters and wires. There are no randomized trials of patients undergoing PCI in which UFH (or other anticoagulant) has been compared to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Dosing and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For PCI, the optimal dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is that which balances the risks of thrombosis and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/25\">",
"     25",
"    </a>",
"    ]. There are no randomized trials comparing different heparin doses or activated clotting time (ACT) goals in patients with stable coronary artery disease and who have been pretreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a thienopyridine. Thus, current recommendations for dosing and monitoring, including those from societal guidelines, are based upon older studies and observational evidence.",
"   </p>",
"   <p>",
"    Monitoring of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    effect is usually performed in an attempt to avoid over or under anticoagulation. When chosen, monitoring is usually performed using the ACT, since the partial thromboplastin time often becomes infinitely prolonged at the high heparin concentrations that are attained in these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Intervention guideline update for PCI recommended that, in patients",
"    <strong>",
"     not",
"    </strong>",
"    receiving a glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, UFH should be given using a weight-adjusted bolus of 70 to 100",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    to achieve an ACT between 250 to 350 seconds (depending upon the ACT device) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/28\">",
"     28",
"    </a>",
"    ]. Further",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    boluses are given if the goal ACT is not achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/29\">",
"     29",
"    </a>",
"    ]. For patients who are treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, the recommended heparin bolus was lowered to 50 to 70",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    and the ACT was targeted at 200 to 250 seconds.",
"   </p>",
"   <p>",
"    The recommendation for 100",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    as the upper limit of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bolus range was supported by findings in the ISAR-REACT 3A study, in which elective PCI with stenting was performed in over 2500 stable patients pretreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ; all patients were given a heparin bolus of 100",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/30\">",
"     30",
"    </a>",
"    ]. Outcomes were compared to those of the heparin (140",
"    <span class=\"nowrap\">",
"     IU/kg)",
"    </span>",
"    cohort in ISAR-REACT 3 trial. The rate of the primary composite endpoint (death, myocardial infarction, urgent target vessel revascularization within 30 days, or major bleeding) was similar in both groups and there was a trend toward a lower rate of bleeding at the lower dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our authors suggest a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bolus of 50 to 70",
"    <span class=\"nowrap\">",
"     IU/kg,",
"    </span>",
"    a dose lower than that in ISAR-REACT 3A, as they are concerned that a dose of 100",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    will lead to an ACT that frequently exceeds the desired ACT goal of&nbsp;&gt;250 to 300 seconds in patients not receiving GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor and 200 to 250 seconds treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. The ACT is checked 10 minutes after the bolus. (See",
"    <a class=\"local\" href=\"#H17964165\">",
"     'GP IIb/IIIa inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38844184\">",
"    <span class=\"h3\">",
"     Patients taking oral anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that at least 5 percent of patients undergoing PCI have been receiving oral anticoagulation for diseases such as atrial fibrillation. The optimal anticoagulant strategy in these patients is unknown and approaches have included discontinuation of oral anticoagulation and bridging with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or continuation of oral anticoagulation with or without additional heparin. A 2010 meta-analysis of eight moderate to low quality studies of patients undergoing elective coronary angiography with or without PCI found that a strategy of uninterrupted vitamin K antagonist (VKA) lowered the risk of access site bleeding by about 50 percent compared to interrupted VKA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal anticoagulant strategy in patients undergoing PCI was addressed in an observational study of 414 patients taking therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (international normalized ratio 2 to 3.5) for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/32\">",
"     32",
"    </a>",
"    ]. Individuals were almost evenly divided between those with stable and unstable disease; 218 patients received additional periprocedural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    while 196 patients did not. In 122 propensity score-matched pairs, there was no significant difference in the rate of major adverse cardiac and cerebrovascular events or Thrombolysis in Myocardial Infarction (TIMI) major bleeding (",
"    <a class=\"graphic graphic_table graphicRef71353 \" href=\"UTD.htm?28/0/28684\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77838 \" href=\"UTD.htm?11/37/11869\">",
"     table 3",
"    </a>",
"    ). However, there was a significantly higher rate of access site complications in those receiving heparin (13 versus 5.7 percent; p = 0.049).",
"   </p>",
"   <p>",
"    Based on limited evidence, we believe it is reasonable to omit",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in stable and unstable patients undergoing PCI who are receiving therapeutic oral anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or those taking therapeutic doses of other oral anticoagulants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1728855140\">",
"    <span class=\"h3\">",
"     Postprocedural management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postprocedural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is not recommended in patients with an uncomplicated procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. There is no evidence that prolonged use of postprocedural heparin or low-molecular weight heparin prevents stent thrombosis or restenosis, and postprocedural heparin is associated with increased bleeding and vascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sheath removal should be accomplished when the activated clotting time (ACT) falls to less than 150 to 180 seconds after the procedure to reduce the incidence of complications at the access site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Heparin-induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is present or suspected, possible substitutions for heparin are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , although only argatroban is approved as adjunctive therapy for PCI in this setting. Low molecular weight heparin is contraindicated in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Enoxaparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although seemingly safe and as effective as unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], the clinical role of low molecular weight heparin remains uncertain as a routine strategy for PCI. It seems reasonable and is probably safer to continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    than switching to heparin once it has been initiated for any reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The REPLACE-2, ISAR-REACT 3, and ACUITY trials evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    as an alternative to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with or without GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients across a broad spectrum of illness severity (stable coronary heart disease to high-risk ACS). Most patients were given a loading dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (either 300 or 600 mg) at least two hours before the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H21648011#H21648011\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Fibrinolytic summary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These trials showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    is similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (statistically non-inferior) for the prevention of ischemic complications in patients undergoing PCI with stenting. In contrast, the rates of protocol-defined major bleeding were lower with bivalirudin. Other advantages of bivalirudin are a lower rate of ischemic and bleeding complications in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/39\">",
"     39",
"    </a>",
"    ] and it is one of the alternatives in patients with known or suspected heparin-induced thrombocytopenia. The only disadvantage of bivalirudin is increased cost.",
"   </p>",
"   <p>",
"    Based upon the available evidence, we recommend anticoagulant therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    (both with pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) in patients with stable angina. The choice of anticoagulant therapy in patients with either non-ST elevation acute coronary syndrome who are selected for an invasive strategy, or those with ST elevation myocardial infarction undergoing primary PCI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H21648011#H21648011\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Fibrinolytic summary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing and dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef64612 \" href=\"UTD.htm?34/50/35628\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged use of antithrombotic therapy with dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) or, on occasion, dual antiplatelet therapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , can lead to both major bleeding, usually in the form of gastrointestinal bleeding, or and minor bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aggressive antithrombotic therapy used in patients undergoing stent implantation, particularly those with ACS, can lead to or exacerbate gastrointestinal bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Minor bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of minor bleeding stems from both the potential progression to major bleeding and the risk of cessation of dual antiplatelet therapy as a consequence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between minor bleeding and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    cessation was evaluated in an observational study of 2360 patients who underwent drug-eluting stent implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients were assessed for the development of alarming (intracranial, life threatening and requiring blood transfusion), internal (hematoma, epistaxis, mouth and vaginal bleeding, melena, eye bleed, hematuria and hematemesis), or nuisance bleeding (easy bruising, bleeding from small cuts, petechia, and ecchymosis) for three years. Bleeding occurred in 32 percent of patients, of which approximately 86 percent was nuisance, 14 percent internal and 1 percent alarming. Clopidogrel discontinuation was reported in 11.1 percent of those with nuisance bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PATIENTS WHO REQUIRE WARFARIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has not been shown to be of benefit in the prevention of stent thrombosis. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clopidogrel'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who receive intracoronary stents and have other indications for anticoagulant therapy, such as atrial fibrillation (AF) or mechanical heart valves, the optimal management of the anticoagulant and antiplatelet regimens is unknown. This is a common problem, as approximately one-third of patients with AF, many of whom are on chronic anticoagulant therapy, have concomitant coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/41\">",
"     41",
"    </a>",
"    ], and it is estimated that five to 10 percent of patients referred for PCI have a strong indication for long-term anticoagulation, such as AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In addition, patients with atrial fibrillation who undergo PCI with stenting are at high risk of adverse events. In a report of 426 such patients, a major adverse cardiovascular event (death, MI, or target lesion revascularization) rate of 32 percent at a median follow up of 595 days after PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/45\">",
"     45",
"    </a>",
"    ]. All-cause mortality was 23 percent.",
"   </p>",
"   <p>",
"    There is substantial evidence that the rate of major bleeding is increased in patients taking two antiplatelet agents plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (triple drug therapy) compared with those not on warfarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H7#H7\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, there is some evidence of a higher rate of adverse cardiovascular events in patients undergoing PCI with stenting who are candidates for triple therapy but are not treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The following observations in two studies of such patients illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study of 239 patients on long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , those who received triple therapy after discharge (compared to those who receive dual antiplatelet therapy) had lower unadjusted rates of stroke and stent thrombosis (2.8 versus 8.8 and 1.9 versus 5.9,) but a higher rate of MI (8.5 versus 5.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 426 patients, dual antiplatelet therapy was associated with a significantly increased risk of major adverse cardiovascular events (death, MI, or target vessel revascularization) compared to triple therapy (38 versus 26 percent; hazard ratio 4.9, 95% CI 2.17-11.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal antithrombotic duration and intensity of a triple-drug regimen in such patients is unknown since adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    increases the bleeding risk, while reducing the intensity of antiplatelet therapy in patients on warfarin will increase the risk of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are candidates for both anticoagulant and antiplatelet therapy, antithrombotic therapy should be individualized in an attempt to balance the risks of major bleeding with the risk of stent thrombosis. In the absence of data, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If time permits,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is discontinued and PCI is not performed until the INR is &lt;1.5. If it is felt that it would be unsafe to withhold anticoagulation for several days (eg, because of a mechanical heart valve), the patient can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin (bridging therapy).",
"     </li>",
"     <li>",
"      If time does not permit waiting for the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to wane, we suggest that the patient accept the increased bleeding risk but often administer fresh frozen plasma if the INR is supratherapeutic. We do not give subcutaneous or intravenous vitamin K since the abrupt normalization of the INR can precipitate thrombotic complications and make it more difficult to reinstitute anticoagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"       \"Therapeutic use of warfarin\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In such patients, we may choose a radial rather than femoral artery approach, since bleeding is more easily controlled. However, a femoral approach can be used with careful front-wall puncture and use of a closure device if appropriate.",
"     </li>",
"     <li>",
"      Patients should be reassessed for their need for chronic anticoagulation prior to reinitiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      is restarted as soon as possible after PCI, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      are continued to minimize the risk of stent thrombosis. We usually aim for an INR on the lower end of the desired range. The duration of triple antithrombotic therapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link&amp;anchor=H13#H13\">",
"       \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'Duration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bare metal stents should be strongly considered in preference to drug-eluting stents (DES) in patients who require prolonged anticoagulation in order to minimize the duration of dual antiplatelet therapy. Patients for whom DES may be preferable include those with long lesions, small vessels, or diabetes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"       \"Use of intracoronary stents for specific coronary lesions\"",
"      </a>",
"      ). This position is advocated in a consensus document of the European Society of Cardiology [",
"      <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The INR should be monitored closely, particularly in the first four weeks after discharge (high risk period for hemorrhage). If the indication for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is atrial fibrillation, we believe that attempting to keep the INR in the 2.0-2.5 range is reasonable while the patients is on both antiplatelet and warfarin therapy.",
"     </li>",
"     <li>",
"      Long term prophylactic proton-pump inhibition should be considered for patients with peptic ulcer disease and who receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      should be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275406809\">",
"    <span class=\"h1\">",
"     PATIENTS UNDERGOING BALLOON ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We estimate that approximately 5 percent of patients who undergo PCI do not receive a stent and are treated with balloon angioplasty. For those patients in whom stenting is intended, pre-procedural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a thienopyridine are appropriate.",
"   </p>",
"   <p>",
"    No randomized trials have directly addressed the optimal long-term antiplatelet strategy in patients who undergo PCI but do not receive a stent. Some experts, including the authors of the Primary and Secondary Prevention of Cardiovascular Disease section of the 2012 American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis guidelines, suggest one month of dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) due to concerns about an increase in thrombotic potential caused by iatrogenic plaque rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/8/27786/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While balloon angioplasty does disrupt the integrity of the vascular endothelium, acute intracoronary thrombosis rarely occurs after 48 hours. Thus, the theoretical benefit from one month of dual antiplatelet therapy must be weighed against the increased risk of bleeding during this time. Based on limited evidence, we suggest one month of dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) in patients not at high risk of bleeding or planned surgery within 30 days; for those with either of these, we suggest dual antiplatelet therapy for at least 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate antithrombotic therapy using antiplatelet and anticoagulant drugs is essential to minimize the risk of coronary artery stent thrombosis while limiting complications of major bleeding. However, even with proper timing and dosing, the risk of stent thrombosis and other ischemic complications, as well as major bleeding, including gastrointestinal bleeding, persists. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H30\">",
"       'Gastrointestinal bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommendations for the periprocedural use of antithrombotic therapy in patients with stable angina follow. The use of these agents in patients with acute coronary syndromes undergoing PCI is found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link\">",
"       \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Recommendations for the long-term use of antiplatelet therapy in stented patients are also presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"       \"Antiplatelet therapy after coronary artery stenting\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      In stable patients in whom PCI with stenting is scheduled or anticipated, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For those patients not on chronic aspirin therapy, as well as for those on a maintenance dose of &lt;325 mg daily, give 325 mg at least two hours before the procedure, if possible. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In stable patients in whom PCI with stenting is scheduled or anticipated, we recommend pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The dose of clopidogrel is 600 mg and it should be given at least two hours before the procedure.",
"     </li>",
"     <li>",
"      For stable patients with a high likelihood of NOT needing PCI, such as those with low risk for significant CAD or who have not had adequate trial of medical therapy or those who have high likelihood of referral for coronary artery bypass graft surgery, we suggest waiting to give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      until after coronary angiography when the decision to perform PCI can be made (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clopidogrel'",
"      </a>",
"      above.) For those patients undergoing coronary arteriography who have not received pretreatment and for whom it is desired to perform PCI immediately, it is reasonable to give clopidogrel 600 mg in the catheterization laboratory and proceed with PCI.",
"     </li>",
"     <li>",
"      For stable patients undergoing PCI who have been taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg per day, we suggest clopidogrel reloading in those at high risk of stent thrombosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Until further data is available, we suggest using 600 mg. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients already taking clopidogrel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend anticoagulant therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      in all patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Parenteral anticoagulant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who because of timing have not received adequate treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , such as those who receive these oral drugs less than two hours before the procedure, we suggest additional treatment with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor at the time of PCI in those at high risk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17964165\">",
"       'GP IIb/IIIa inhibitors'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The addition of GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor therapy may also be appropriate for patients who by angiographic criteria are at high risk for a stent thrombosis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Elective stenting'",
"      </a>",
"      above.) The doses and timing are presented separately (",
"      <a class=\"graphic graphic_table graphicRef64612 \" href=\"UTD.htm?34/50/35628\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who undergo PCI without stent placement (balloon angioplasty alone) and who are not at high risk of bleeding or planned surgery within 30 days, we suggest dual antiplatelet therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      for 30 days after the procedure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients at high bleeding risk or in whom surgery is anticipated within 30 days, dual antiplatelet therapy for less than 30 days or single antiplatelet therapy are reasonable options.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3777181\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/1\">",
"      Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/2\">",
"      Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/3\">",
"      Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999; 281:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/4\">",
"      Scrutinio D, Lagioia R, Rizzon P. Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. Eur Heart J 1991; 12 Suppl G:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/5\">",
"      Alonso-Martinez JL, Elejalde-Guerra JI, Larr&iacute;naga-Li&ntilde;ero D. Bronchiolitis obliterans-organizing pneumonia caused by ticlopidine. Ann Intern Med 1998; 129:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/6\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/7\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/8\">",
"      Collet JP, Silvain J, Landivier A, et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study. Circulation 2008; 118:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/9\">",
"      Di Sciascio G, Patti G, Pasceri V, et al. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. Eur Heart J 2010; 31:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/10\">",
"      Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/11\">",
"      Sapirstein W, Zuckerman B, Dillard J. FDA approval of coronary-artery brachytherapy. N Engl J Med 2001; 344:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/12\">",
"      Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/13\">",
"      Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/14\">",
"      Lange RA, Hillis LD. The Duel between Dual Antiplatelet Therapies. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/15\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/16\">",
"      Kastrati A, Mehilli J, Sch&uuml;hlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/17\">",
"      Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/18\">",
"      Puma JA, Banko LT, Pieper KS, et al. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J Am Coll Cardiol 2006; 47:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/19\">",
"      PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001; 141:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/20\">",
"      ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/21\">",
"      Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/22\">",
"      Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/23\">",
"      Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/24\">",
"      Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:728S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/25\">",
"      Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/26\">",
"      Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114:489S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/27\">",
"      Oltrona L, Eisenberg PR, Lasala JM, et al. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996; 94:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/28\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/29\">",
"      Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/30\">",
"      Schulz S, Mehilli J, Neumann FJ, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/31\">",
"      Jamula E, Lloyd NS, Schwalm JD, et al. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis. Chest 2010; 138:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/32\">",
"      Kiviniemi T, Karjalainen P, Pietil&auml; M, et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol 2012; 110:30.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/34\">",
"      Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/35\">",
"      Rabah M, Mason D, Muller DW, et al. Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999; 34:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/36\">",
"      Friedman HZ, Cragg DR, Glazier SM, et al. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994; 24:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/37\">",
"      Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/38\">",
"      Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/39\">",
"      Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003; 92:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/40\">",
"      Roy P, Bonello L, Torguson R, et al. Impact of \"nuisance\" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008; 102:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/41\">",
"      Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv 2008; 1:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/42\">",
"      Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/43\">",
"      Rubboli A, Colletta M, Valencia J, et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009; 22:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/44\">",
"      Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008; 155:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/45\">",
"      Ruiz-Nodar JM, Mar&iacute;n F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/46\">",
"      Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/8/27786/abstract/47\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1576 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27786=[""].join("\n");
var outline_f27_8_27786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      P2Y12 RECEPTOR BLOCKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Timing and dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Patients already taking clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Possible CABG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clopidogrel resistance/nonresponse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adverse interaction with proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intracoronary radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1142865664\">",
"      - Prasugrel and ticagrelor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1142865718\">",
"      - Cangrelor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17964165\">",
"      GP IIB/IIIA INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Elective stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk for bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PARENTERAL ANTICOAGULANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Dosing and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38844184\">",
"      - Patients taking oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1728855140\">",
"      - Postprocedural management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Enoxaparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Minor bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PATIENTS WHO REQUIRE WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H275406809\">",
"      PATIENTS UNDERGOING BALLOON ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3777181\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1576\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1576|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/9/4254\" title=\"figure 1\">",
"      Clopidogrel in CREDO 28 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/47/33533\" title=\"figure 2\">",
"      Clopidogrel timing before PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1576|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/23/32118\" title=\"picture 1\">",
"      Clopidogrel generalized exanthema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1576|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/50/35628\" title=\"table 1\">",
"      Parenteral rx elective PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/0/28684\" title=\"table 2\">",
"      Definitions major bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/37/11869\" title=\"table 3\">",
"      BARC definition for bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26232?source=related_link\">",
"      Hypersensitivity reactions to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/9/20632?source=related_link\">",
"      Periprocedural and long-term gastrointestinal bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25560?source=related_link\">",
"      Use of intracoronary radiation to prevent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_8_27787="History taking in women with pseudocyesis";
var content_f27_8_27787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psychological themes relevant to pseudocyesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Psychological themes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relevant questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure to be pregnant",
"       </td>",
"       <td>",
"        How do significant others feel about the patient's pregnancy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fear of pregnancy",
"       </td>",
"       <td>",
"        Does the patient have concerns/fears about pregnancy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coping style characterized by somatization and/or denial",
"       </td>",
"       <td>",
"        How does the patient characteristically manage difficult emotions?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loneliness",
"       </td>",
"       <td>",
"        Does the patient have adequate social support?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss",
"       </td>",
"       <td>",
"        Is there a history of loss (eg, pregnancy loss, deaths, loss of custody of a child, loss of reproductive capacity)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rejection",
"       </td>",
"       <td>",
"        Has the patient been rejected by her partner or someone else important to her?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-identity",
"       </td>",
"       <td>",
"        What role does fertility and pregnancy play?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"       <td>",
"        Is there a history of abuse (physical, sexual)?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27787=[""].join("\n");
var outline_f27_8_27787=null;
var title_f27_8_27788="Clinical features distinguishing T1DM T2DM MODY";
var content_f27_8_27788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features distinguishing type 1 diabetes, type 2 diabetes, and maturity onset diabetes of the young",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 1 diabetes mellitus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 2 diabetes mellitus",
"       </td>",
"       <td class=\"subtitle1\">",
"        MODY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of diagnosis (years)",
"       </td>",
"       <td>",
"        Majority &lt;25, but may occur at any age",
"       </td>",
"       <td>",
"        Typically &gt;25 but incidence is increasing in adolescents, paralleling increasing rates of obesity in children and adolescents*",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight",
"       </td>",
"       <td>",
"        Usually thin, but with obesity epidemic overweight and obesity at diagnosis becoming more common",
"       </td>",
"       <td>",
"        &gt;90 percent at least overweight",
"       </td>",
"       <td>",
"        Similar to general population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoantibodies",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin dependent",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin sensitivity",
"       </td>",
"       <td>",
"        Normal when controlled",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Normal (may be decreased if obese)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of diabetes",
"       </td>",
"       <td>",
"        Infrequent (5 to 10 percent)",
"       </td>",
"       <td>",
"        Frequent (75 to 90 percent)",
"       </td>",
"       <td>",
"        Multigenerational, ie, &gt;2 generations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of diabetic ketoacidosis",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MODY: maturity onset diabetes of the young.",
"     <br/>",
"     * In North America, type 2 diabetes predominates in Hispanic, African-American, Native American, Canadian First Nation, Pacific Islander, and Asian-American youth.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Naylor R, Philipson LH. Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf) 2011; 75:422.",
"      </li>",
"      <li>",
"       Ramesh SC, Marshall I. Clinical Suspicion of Maturity Onset of Diabetes of the Young in Pediatric Patients Diagnosed with Diabetes Mellitus. Indian J Pediatr 2011; Dec 10 [ePub].",
"      </li>",
"      <li>",
"       Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011; 343:d6044.",
"      </li>",
"      <li>",
"       Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr 2005; 146:693.",
"      </li>",
"      <li>",
"       De Ferranti  SD, Osganian SK. Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4:285.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27788=[""].join("\n");
var outline_f27_8_27788=null;
var title_f27_8_27789="Micro pharyngitis children";
var content_f27_8_27789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common infectious causes of acute pharyngitis in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical clues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus",
"        </em>",
"        , group A*",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Tonsillopharyngitis and scarlet fever",
"       </td>",
"       <td>",
"        Acute onset, fever, headache, abdominal pain, tonsillopharyngeal erythema and exudate, tender anterior cervical lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Streptococcus",
"        </em>",
"        , groups C and G",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Tonsillopharyngitis and scarlatiniform rash",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Neisseria gonorrhoeae",
"        </em>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Pharyngitis",
"       </td>",
"       <td>",
"        Oral-genital contact in sexually active adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Corynebacterium diphtheriae",
"        </em>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Diphtheria",
"       </td>",
"       <td>",
"        Tightly adherent membrane in nose and throat; history of travel (particularly to former Soviet Union, Africa, or Asia), lack of immunizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Arcanobacterium haemolyticum",
"        </em>",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Pharyngitis and scarlatiniform rash",
"       </td>",
"       <td>",
"        More common in adolescents; rash occurs in approximately one-half",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tularemia",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Ulcerative-exudative pharyngitis",
"       </td>",
"       <td>",
"        Ingestion of poorly cooked wild animal meat or contaminated water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Atypical bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Pneumonia, bronchitis, and pharyngitis",
"       </td>",
"       <td>",
"        Adolescents and adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhinovirus",
"       </td>",
"       <td>",
"        Common cold",
"       </td>",
"       <td>",
"        Nasal symptoms predominate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coronavirus",
"       </td>",
"       <td>",
"        Common cold",
"       </td>",
"       <td>",
"        Nasal symptoms predominate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory syncytial virus",
"       </td>",
"       <td>",
"        Bronchiolitis, common cold",
"       </td>",
"       <td>",
"        Nasal symptoms predominate; seasonal epidemics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenovirus",
"       </td>",
"       <td>",
"        Pharyngoconjunctival fever and acute respiratory disease",
"       </td>",
"       <td>",
"        Conjunctivitis, tonsillopharyngeal erythema and exudates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes simplex virus types 1 and 2",
"       </td>",
"       <td>",
"        Gingivostomatitis",
"       </td>",
"       <td>",
"        Discrete ulcers or vesicular lesions throughout oral cavity, including in the anterior pharynx; exudative tonsillopharyngitis in sexually active adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parainfluenza",
"       </td>",
"       <td>",
"        Common cold and croup",
"       </td>",
"       <td>",
"        Stridor, hoarseness, prominent nasal symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza A and B viruses",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Influenza",
"       </td>",
"       <td>",
"        Fever, cough, pharyngitis, headache, myalgia; seasonal epidemics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteroviruses (Coxsackie A)",
"       </td>",
"       <td>",
"        Herpangina and hand-foot-and-mouth disease",
"       </td>",
"       <td>",
"        Vesicles in posterior pharynx may be accompanied by lesions on hands and feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein-Barr virus",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Infectious mononucleosis",
"       </td>",
"       <td>",
"        Fever, severe pharyngitis, frequent exudates, anterior and posterior cervical lymphadenopathy, prominent constitutional symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"       <td>",
"        Infectious mononucleosis",
"       </td>",
"       <td>",
"        Fever, mild or no pharyngitis, anterior and posterior cervical lymphadenopathy, prominent constitutional symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human immunodeficiency virus (HIV)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Primary HIV infection",
"       </td>",
"       <td>",
"        Mononucleosis-like syndrome with fever, weight loss, diffuse adenopathy, rash, splenomegaly, lymphopenia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common cause requiring antimicrobial therapy.",
"     <br>",
"      &bull; Identification is important for treatment or infection control purposes (see text for details).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27789=[""].join("\n");
var outline_f27_8_27789=null;
var title_f27_8_27790="Superficial burn PI";
var content_f27_8_27790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superficial burns are red, and they turn white when you press them.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27790=[""].join("\n");
var outline_f27_8_27790=null;
var title_f27_8_27791="Ulcerations LV";
var content_f27_8_27791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerations in livedoid vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shallow ulcers over the dorsal feel with postinflammatory hyperipigmentation and stellate scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hairston, BR, et al. Treatment of livedoid vasculopathy with low-molecular weight heparin. Arch Dermatol 2003 139:987. Copyright &copy;2003 American Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_8_27791=[""].join("\n");
var outline_f27_8_27791=null;
